

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

DRAGON PHARMACEUTICAL INC
Form 10KSB
April 03, 2006

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 10-KSB

ANNUAL REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For The Fiscal Year Ended December 31, 2005
Commission File Number 0-27937

Dragon Pharmaceutical Inc.

(Exact name of small business issuer)

Florida

(State of other jurisdiction of incorporation or
organization)

65-0142474

(I.R.S. Employer
Identification Number)

650 West Georgia Street, Suite 310
Vancouver, British Columbia V6B 4N9

(Address of Principal Executive Offices)

www.dragonpharma.com

(Registrant's Internet Address)

(604) 669-8817

(Registrant's telephone number including area code)

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act: Common Stock, par
value \$0.001

Check whether the issuer is not required to file reports pursuant to Section 13
or Section 15(d) of the Exchange Act. []

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the issuer was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.

Yes X No

Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. []

Indicate by check mark whether the registrant is a shell Company: Yes No X

Our revenues for the year ended December 31, 2005 was \$56,237,000.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

State the aggregate market value of the voting and non-voting common equity held by non-affiliates, computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of March 15, 2006 was \$10,773,120.

The number of shares outstanding of the issuer's common stock as of March 15, 2006, was 62,878,004.

Documents incorporated by reference: None

Transitional Small Business Disclosure Format: Yes ----- No. X -----

1

TABLE OF CONTENTS

PART I
ITEM 1. DESCRIPTION OF BUSINESS.....
ITEM 2. DESCRIPTION OF PROPERTY.....
ITEM 3. LEGAL PROCEEDINGS.....
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.....
PART II
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.....
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.....
ITEM 7. FINANCIAL STATEMENTS.....
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS AND FINANCIAL DISCLOSURE...
ITEM 8A. CONTROLS AND PROCEDURES.....
ITEM 8B. OTHER INFORMATION.....
PART III
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.....
ITEM 10. EXECUTIVE COMPENSATION.....
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS.....
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.....
ITEM 13. EXHIBITS

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.....

2

PART I

ITEM 1. DESCRIPTION OF BUSINESS

With the exception of historical facts stated herein, the following discussion may contain forward-looking statements regarding events and financial trends that may affect Dragon Pharmaceutical Inc.'s future operating results and financial position. Such statements are subject to risks and uncertainties that could cause Dragon Pharmaceutical Inc.'s actual results and financial position to differ materially from those anticipated in such forward-looking statements. Factors that could cause actual results to differ materially include, in addition to other factors identified in this report, that Dragon Pharmaceutical has incurred losses since its inception, has a substantial amount of liabilities, and has recently completed its acquisition of Oriental Wave Holding, Ltd., all of which factors are set forth in more detail in the sections entitled "Item 1. Business Risks Associated With Dragon Pharmaceutical" and "Item 6. Management's Discussion and Analysis or Plan of Operation" herein. Readers of this annual report are cautioned not to put undue reliance on "forward looking" statements that are, by their nature, uncertain as reliable indicators of future performance. Dragon Pharmaceutical Inc.'s disclaims any intent or obligation to publicly update these "forward looking" statements, whether as a result of new information, future events, or otherwise.

As used in this annual report, the terms "we", "us", "our", "the Company" and "Dragon" shall mean Dragon Pharmaceutical Inc. and its subsidiaries unless otherwise indicated. Further, unless otherwise indicated, reference to dollars shall mean United States dollars.

General

We are a diversified pharmaceutical company with three key business units consisting of a Chemical division for bulk Active Pharmaceutical Ingredient (API) and pharmaceutical intermediates, a Biotech Division for biologics and a Pharma division for formulated generic drugs, such as powder for injections and oral formulations.

Dragon currently has four production facilities in Datong, China, including three GMP production facilities certified by Chinese State Food and Drug Administration ("SFDA") : a pharmaceutical facility with a capacity of producing tablets, capsules, powder for injectables and suppositories, one biotech facility producing Erythropoietin ("EPO") injectables and one chemical facility producing bulk clavulanic acid. The fourth facility produces bulk 7-ACA, an intermediate for Cephalosporin antibiotics by a fermentation process. 7-ACA is an intermediate and no GMP is required for the production facility. The Company now has 329 drugs approved by the Chinese SFDA of which 101 are sold in the Chinese markets while products from the Chemical and Biotech division are also sold in selected international markets.

As discussed below, the Company completed the acquisition of Oriental Wave Holding Ltd. ("Oriental Wave") on January 12, 2005 which transformed us from a single product company into a diversified pharmaceutical company with three key business units consisting of a Biotech Division for biotech products, a Chemical division for bulk pharmaceutical intermediate and API and a Pharma division for formulated generic drugs, such as powder for injections and oral formulations.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

The Company's headquarters, located in Vancouver, accommodates corporate functions such as financial reporting, SEC compliance, corporate finance, investor relations, international sales and marketing and regulatory affairs for international product approval. The Company also has a Corporate office in Beijing, China to manage all the businesses in China including strategy formulation in the Chinese market, product development, production and sales and marketing management. Through the acquisition, the Company has significantly increased the size of operations through Oriental Wave with approximately 1,800 employees, over 1,200 contract sales representatives in China, and approximately 63 key products in 101 different dosages and presentations currently in the

3

market. The Company maintains a sales network of over 1,200 sales representatives in 63 contracted sales offices throughout China for Pharma products sales and marketing, while it uses a direct sales model through the in-house sales department to sell Chemical products to other domestic and international pharmaceutical companies.

Corporate History

The Company was originally formed on August 22, 1989, as First Geneva Investments, Inc. First Geneva Investments was formed for the purpose of evaluating and acquiring businesses. On August 17, 1998, the Company acquired Allwin Newtech Ltd., a British Virgin Islands corporation. Allwin Newtech Ltd. was formed on February 10, 1998, for the purpose of developing pharmaceutical products in China. Allwin Newtech owns certain technology used to enhance the efficiency of producing EPO. On September 21, 1998, First Geneva Investments changed its name to Dragon Pharmaceutical Inc.

On January 12, 2005, we completed the acquisition of Oriental Wave. Oriental Wave is principally engaged in the production and sale of pharmaceutical products. In connection with the acquisition of Oriental Wave, the Company issued 44,502,004 shares of common stock to the three prior owners of Oriental Wave. As a result, these three prior owners of Oriental Wave collectively own 70.78% of our outstanding shares. The acquisition of Oriental Wave allows us to expand our range of products, leverage both companies' marketing networks in China and in international markets, and improve our ability to execute our combined business strategy.

Oriental Wave, incorporated in the British Virgin Islands, is a holding company of Shanxi Weiqida Pharmaceutical Ltd. ("Shanxi Weiqida"), a China based pharmaceutical company engaged in the production, marketing and sale of pharmaceutical intermediates, active pharmaceutical ingredients and generic formulation drugs.

Significant subsidiary

Shanxi Weiqida Pharmaceutical Ltd. ("Shanxi Weiqida") was primarily formed and organized through the acquisition of assets from three Chinese companies. Two of these acquisitions were completed out of bankruptcy procedures of state-owned pharmaceutical companies.

Shanxi Weiqida was formed in January 2002 as a Chinese domestic company. At the time it was established, Shanxi Weiqida acquired, for no cost, from Shanxi Tongling Pharmaceutical Co., Ltd., or Shanxi Tongling, all drug production permits, and product licenses of Datong No. 2 Pharmaceutical Factory, or Datong No. 2 Pharmaceutical. The assets of Datong No. 2 Pharmaceutical were acquired by Shanxi Tongling in June 2001 out of bankruptcy for RMB 42.3 million, or approximately \$5.1 million. Shanxi Tongling was founded in 1994 by Mr. Han, our current Chief Executive Officer.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

In April 2002 Shanxi Weiqida acquired from Shanxi Tongzhen Pharmaceutical Co. Ltd., or Shanxi Tongzhen, all of its product licenses and production permits in consideration for assuming approximately RMB 6.7 million, or approximately \$0.8 million, of bank debt upon the liquidation of Shanxi Tongzhen.

In June 2002, Shanxi Weiqida purchased the assets relating to a capsules and injectables production line, including certain equipment, inventory, receivables and product licenses and related production permits, from Aurobindo Tongling (Datong) Pharmaceutical Co., Ltd., or Aurobindo Tongling (Datong), for consideration of approximately RMB 33.75 million, or approximately \$4.1 million. At the time of the transaction, Mr. Han was also the Chairman of Aurobindo Tongling (Datong).

4

In August 2002, the control of Shanxi Weiqida was transferred to Canadian First Pharmaceutical Co., Ltd., or Canadian First Pharmaceutical, and Shanxi Weiqida was re-established as a Wholly Foreign Owned Enterprise under Chinese Law. Canadian First Pharmaceutical was controlled by Mr. Han. As a result, Canadian First Pharmaceutical became the holding company of Shanxi Weiqida and had no other operations or business other than Shanxi Weiqida. In March 2003, Canadian First Pharmaceutical transferred its entire ownership in Shanxi Weiqida to Oriental Wave. Oriental Wave has no other operations or business other than Shanxi Weiqida.

In September 2002, Shanxi Weiqida acquired out of bankruptcy all assets of Datong Pharmaceutical Factory, or Datong Pharmaceutical, a state-owned enterprise, including the land use rights of Datong Pharmaceutical. Pursuant to the acquisition agreement entered into with the Datong Economic Committee of the Datong Municipal Government, Shanxi Weiqida acquired the assets in consideration for assuming all liabilities related to the employees of Datong Pharmaceutical. The agreement requires Shanxi Weiqida to pay the former employees of Datong Pharmaceutical certain minimum wages and health care costs until the date of their re-employment, retirement or death, whichever occurs first. Shanxi Weiqida has arranged for the re-employment or retirement of approximately 85% of the Datong Pharmaceutical employees.

In February 2003, Shanxi Weiqida commenced construction of a Clavulanic acid manufacturing facility, which was completed in August 2003. Pilot production began in August 2003 and full-scale production began in January 2004. Construction of Shanxi Weiqida's 7-ACA workshop was completed in December 2003 and pilot production of 7-ACA commenced on July 1, 2004. In July 2005, the Company started to ramp up the production.

As a result of the acquisitions and expansions described above, Shanxi Weiqida has developed into a comprehensive, integrated GMP certified pharmaceutical and development company. Shanxi Weiqida owns production capabilities to manufacture both pharmaceutical drugs and bulk pharmaceutical API and pharmaceutical intermediates through its Pharma Division and Chemical Division. In its 258,300 square feet manufacturing campus, the Pharma Division operates one powder for injection workshop, one general formulation workshop and one sterilized bulk drug workshop. In its 818,100 square feet manufacturing campus, the Chemical Division produces Clavulanic Acid and 7-ACA.

In August, 2005, the Company closed its Biotech production facility in Nanjing, China and started the relocation of the Biotech production facility to a site next to the Chemical Division campus in Datong, China. The new Biotech production facility was completed at the end of December, 2005 and the Company received the GMP certification for this new facility from the Chinese SFDA on December 29, 2005. It is expected that production at this new facility will

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

begin during the first quarter of 2006.

Shanxi Weiqida's head office is located in a special economic region in China. According to the tax laws for foreign enterprises, Shanxi Weiqida was granted a two-year national income tax exemption beginning in the first year after it became profitable and a 50% national income tax reduction for the following three years. Shanxi Weiqida became profitable in 2003. According to the current tax policy, the applicable tax rate for Shanxi Weiqida for 2005, 2006 and 2007 is 18%.

Business Segments

The Company operates three key business units consisting of a Chemical division for bulk pharmaceutical API and intermediate such as Clavulanic acid and 7-ACA, a Pharma division for formulated drugs, including prescription drugs, over-the-counter drugs, and sterilized bulk drugs and a Biotech division for biologics products, such as Erythropoietin or EPO.

5

Chemical Division

The Chemical Division's facilities are located on Datong Gongnong Road, Datong City, Shanxi Province, China. The Chemical Division produces the bulk pharmaceutical intermediates and API to sell to other pharmaceutical companies for further processing and formulation into finished products. The Chemical Division manages the production of Clavulanic acid and 7-ACA for both Chinese and international markets. The designed production capacity for Clavulanic Potassium and 7-ACA were 30 tons and 400 tons respectively. After the Company's investment in the process optimization and technology improvement, the current production capacity reaches 50 tons and 600 tons for Clavulanic Potassium and 7-ACA respectively. The production for Clavulanic Acid was started in January 2004 and the production of 7-ACA was started in July 2004. One of the key products in Chemical Division is Clavulanic acid, a drug that combines with antibiotics increase the effectiveness of the antibiotics. Dragon is currently the only producer of Clavulanic acid in China. Another key product in the Chemical Division is 7-ACA, an intermediate for Cephalosporin antibiotics. The 600-ton production capacity of 7-ACA positions Dragon among the main producers in the world. The export of 7-ACA to India commenced in 2004. In 2004, Dragon's Chemical Division entered into a 3-year long term supply agreement with a large Indian pharmaceutical company and the Company currently set a target to sell 50% of production to the Indian market. The Chemical Division operates its business strategies to upgrade its technology in order to improve yields and lower production cost, to develop 7-ACA and Clavulanic acid downstream bulk products, and to apply for approvals in the US and EU to enter into European and North American markets.

On June 30, 2004, the Company also entered a non-binding letter of intent with an arm's length customer to provide this customer with third party manufacturing services for the production of Abamectin, an antibiotics used in agriculture. The production facility was completed by the customer but the customer is in the process of reconsidering the product portfolio to be produced in such facility due to the market condition of Abamectin. It is expected that the production in such facility will be delayed towards the end of 2006.

Pharma Division

The Pharma Division's operations are located in the Datong Economic and Technology Development Zone, Datong City, Shanxi Province, China. Pharma Division produces chemical generic, mainly anti-infectious, drugs. The Pharma Division currently holds approximately 319 product approvals from SFDA, of which

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

only 85 prescription, over-the-counter and sterilized bulk products in different dosages and presentations are currently commercialized in China. At the end of December, 2005, the Company completed a new workshop for the freeze-drying of temperature sensitive pharmaceutical products. Among these products is Levofloxacin, a product marketed by the Company whose production was outsourced to a third party contract manufacturer. The Pharma Division operates its business strategies to focus on the expansion and development of the Chinese market by managing its product portfolio and selecting potential products for commercialization.

Biotech Division

The Biotech Division's facility was relocated to Datong, China from its original production site in Nanjing City, China at the end of December, 2005. The new EPO production site is adjacent to the campus of the Chemical division, which already includes the entire basic infrastructure such as power, steam, purified water supply and water treatment facilities. The relocation of the EPO production site to Datong will allow the Company to capitalize on the existing production infrastructure and the efficiency of unified operational management. In the new facility, it is anticipated that the capacity for bulk EPO will be doubled to 120 grams and the capacity for sterile vialing will be tripled to 5 million vials. The sole product of the Biotech Division is Erythropoietin or EPO, an injectable that stimulates red blood cell development. Dragon's Biotech Division develops, manufactures and markets generic EPO with China and developing countries as the current core markets, and has already been approved and sold in 9 countries: China, India, Egypt, Brazil, Peru, Ecuador,

6

Trinidad-Tobago, Dominican Republic and Kosovo. Currently, Dragon's EPO is sold only in countries where there is no patent protection. In the past, Dragon was preparing to enter the European market with a new EPO product under development in Austria. However, in January 2006, the Company sold the development contract with the Austrian partner to a related party for \$1 million cash and assumption of all obligations under the contract. (See "Certain Relationship And Related Transactions")

The Biotech Division operates its business strategies to increase market share through the integration of its sales network with the Pharma division and to increase the sales in surgical usage as one of the two approved surgical indication suppliers.

Products

The following table describes the top five products of the Company in terms of revenue contribution.

No.	Drug Name	Category	Presentation	Treatment	% of 2
---	-----	-----	-----	-----	-----
1.	7-ACA	Pharmaceutical Intermediate	Bulk	An intermediate for Cephalosporin antibiotics.	
2.	Clavulanic Acid	API	Bulk	For use together with antibiotics to make the antibiotics more effective and longer-lasting	

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

		----- Cloxacillin (1)	----- Nitroimidaz
----- Aminoglycosides		----- Ampicillin Cloxacillin (1)	----- Nitrofurans
----- Amphenicols		----- Amoxicillin	
----- Tetracyclines		----- Phenoxvnethu Penicillin Pottasium (1)	
		----- Amoxicillin Clavulanate Potassium (1)	
----- Macrolides(1) -----		----- Ceftriaxon (1)	
		----- Cefadroxl (1)	
		----- Cefotaxime Sodium (1)	
		----- Roxithromycin (1)	
----- Others(1)-----		----- Fosformycin Sodioum (1)	

(1) Products produced by Shanxi Weiqida

Chemical Division

The Chemical Division currently produces Clavulanic acid and 7-ACA. Clavulanic acid is used together with antibiotics to make the antibiotics more effective and longer-lasting. 7-ACA is an intermediate which is converted into active pharmaceutical ingredients to produce Celphalosporin antibiotics.

Clavulanic acid. Beta-lactam antibiotics, such as the penicillins and cephalosporins, act by disrupting the development of bacterial cells walls thus causing the disintegration of the bacteria. However, some bacteria have acquired the genes to produce enzymes which inactivate this mode of action - so called beta-lactamases and thus drastically reducing the efficacy of this class of antibiotics. Clavulanic acid acts to inhibit the effectiveness of bacterial beta-lactamases since they are much more inclined to bond to Clavulanic acid than to beta-lactam antibiotics. In this way, bacterial beta-lactamases miss their target and the antibiotic has free access to the bacterial wall which it affects.

The Company's Clavulanic acid technology and production process was licensed and transferred from Alpha Process Trust Reg., or Alpha Trust. With the commencement of the production of Clavulanic acid in January 2004, the Company

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

became the first commercial scale producer in China. By being the first producer in China, the Company believes it has a competitive advantage over other manufacturers to fulfill demands for Clavulanic acid domestically as well as internationally.

7-ACA.7 -ACA is made from Cephalosporin C and is a key intermediate for synthesizing cephalosporin antibiotics, the a-lactam antibiotics family. Target the synthesis of peptidoglycan layer of the bacterial cell wall. Produced by the fermentation of a filamentous fungus (Cephalosporium acremonium now known as Acremonium chrysogenum), cephalosporin C in the fermentation broth is isolated from the biomass by filtration. The strongly hydrophilic Cephalosporin C is purified by laborious adsorption and ion exchange steps. Cephalosporin C can be a free acid or a salt (sodium, potassium or zinc). The conversion of Cephalosporin C to 7-ACA has 2 methods, chemical process, and enzymatic process. The Company adopts the chemical process in the conversion of Cephalosporin C.

Biotech Division

The Company's primary product of the Biotech division is EPO, a glycoprotein that stimulates and regulates the rate of formation of red blood cells. In adult humans, EPO is produced by the kidneys and acts on precursor cells to stimulate cell proliferation and differentiation into mature red blood cells. Kidney disease and chemotherapy or radiation therapy for treating cancer may impair the body's ability to produce EPO and, in turn, reduce the level of red blood cells to less than one-half that of healthy humans. The shortage of red blood cells leads to insufficient delivery of oxygen throughout the body. The result is anemia, which symptoms include fatigue and weakness.

One of the treatments for anemia is to provide EPO protein. This treatment is administered through dialysis tubing or by injection approximately three times per week. EPO is most commonly administered to people with chronic renal failure, HIV patients being treated with anti-viral drugs, and cancer patients on chemo or radiation therapy. The treatment is less dangerous and generates fewer adverse side effects than alternative treatments that include blood transfusions and androgen therapy. However, side effects of EPO may include hypertension, headaches, shortness of breath, diarrhea, rapid heart rate and nausea.

While EPO has been tested to be effective in treating anemia, there are other drugs and treatments currently that exist or are in development that can treat anemia. These alternative drugs or treatments could be proven more effective, less expensive or preferable to customers than EPO. The inability of EPO to compare favorably to these alternative drugs could have an adverse affect on our business.

9

Sales and Marketing

Sales from the Pharma Division are made solely in China and from the Chemical and Biotech Divisions in China and overseas. The table below sets forth the Company's sales by product segments:

	2004		2005	
	\$ Million	%	\$ Million	%
Pharma Division				
China	24.77	100%	25.08	100

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

International (outside of China)	-			
Chemical Division				
China	2.80	66%	17.69	65%
International (outside of China)	1.45	34%	9.64	35%

Biotech Division				
China	-		3.02	79%
International	-		0.81	21%

Total	29.02	100%	56.24	100%

All above sales of the Pharma Division and the Chemical Division were made in China. The Company expects to add international sales in the coming futures as the Company is actively exploring the unregulated markets, such as India and other developing countries, for the Chemical division products and will eventually extend its market coverage to regulated markets such as Europe and North America.

During 2004 and 2005, sales to the Company's five largest customers accounted for approximately 12.4% and 32.9% of the Company's sales, respectively; while sales to the Company's largest customer accounted for approximately 2.7% and 11.9% of the Company's sales, respectively. Currently, except for the Aurobindo Biopharma contract, the Company has historically made its sales through purchase orders and not through long-term contracts.

Sales Models

The Company maintains different sales and distribution models for the Pharma, Biotech and Chemical Divisions. For the Pharma and Biotech Divisions, the Company sells through sales agents or its 63 sales offices throughout China. Each sales office is managed by a Sales Manager employed by the Company, who is responsible for marketing, promoting and selling the division's products as well as managing sales representatives. The Company has over 1,200 sales representatives located throughout China. These sales representatives pay regular site visits to pharmacy wholesalers and retailers, hospitals and distributors to conduct market research, gather opinions on products and promote the Company's products.

For the Chemical Division, the Company uses a direct sales model with sales made through the sales department located in Datong City. The customers for the Chemical Division are other pharmaceutical companies which will use the products for further processing and formulation.

Pricing Policy

Approximately 46 out of the 89 products from the Pharma Division and Biotech Division of the Company, accounting for approximately 34% of 2004 company total sales and 27% of 2005 company total sales, are subject to retail price controls imposed by the government administration authorities or other relevant authorities in China. The main objective of price control policy is to set an upper limit to the retail prices of pharmaceutical products in order to prevent excessive increases in the prices of pharmaceutical products. The Company's products from Chemical Division are not subject to retail price control and are market-priced products.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Facilities

The Company has a headquarters in Vancouver, Canada to provide certain corporate functions of the Company, such as Finance, Investor Relations, International Regulatory Affairs and International marketing. The Company has one manufacturing facility for the Pharma Division and two manufacturing facilities for the Chemical Division in Datong, China. The Company's biotech facility was originally located in Nanjing, China but was closed in August, 2005 and relocated to Datong, China.

Company's manufacturing facility of the Pharma Division has a size of approximately 258,300 square feet and is located in the Datong Economic and Technology Development Zone in Datong City, Shanxi Province of China. This fully-integrated facility includes an office building, three production workshops (formulation drugs, sterilized bulk drugs and powder for injections) that house a total of eight production lines (four in the formulations workshop, one in the sterilized bulk drugs workshop and three in the powder for injections workshop), utility infrastructure, quality assurance and quality control and warehouse area. The Company holds the land use right for this facility until June 2047.

Company's Chemical and Biotech Division facilities are also located in Datong City. This campus, with a total area of approximately 947,200 square feet, houses the Clavulanic acid production facility, power, boiler, steam and water facilities and 7-ACA production facility and EPO production facility. The land use right for this facility expires in August 2053.

All manufacturing facilities of the Company that are required to be GMP certified, have been certified under current Chinese regulations. Company's GMP certificate for the Pharma Division facility will expire and is subject to recertification in August 2008 and the GMP certificate for the Clavulanic acid facility of the Chemical division will expire and is subject to recertification in January 2009. The Company was granted the GMP certificate for its biotech facility on December 29, 2005. Such GMP certificate will expire and is subject to recertification in December 2010. The 7-ACA facility does not need to be GMP certified. All the facilities of the Company have been designed to meet potential production demands into the foreseeable future.

Competition

Chemical Division

Clavulanic acid. The world production of Clavulanic acid is dominated by manufacturers located in Europe. Among them, Lek Pharmaceutical and Chemical Company of Slovenia, SmithKline Beecham Pharmaceuticals of Britain, Deva Holding A.S. of Turkey, Amifarma S.L. of Spain and DSM of the Netherlands, are the leading manufacturers of Clavulanic acid.

There are currently only four companies that obtained the product approval of bulk Clavulanic acid in China. The Company is currently the only manufacturer of such product in China. However, it is expected that Zhangjiakou International

Pharmaceutical, Shanghai Antibiotics and Zhuhai Lianbang Pharmaceutical will enter the Chinese market during 2006.

7-ACA

Production of 7-ACA is concentrated among a few European and Chinese

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

manufacturers. The Company will face significant competition from these companies. The Company's competitors include Antibioticos, a subsidiary of the Fidia Group of Italy and Biochemie, a subsidiary of Novartis of Switzerland. In addition, in the Chinese market there are four leading Chinese manufacturers: China Pharmaceutical, Shangdong Lukang Pharmaceutical, Fuzhou Pharmaceutical and Harbin Pharmaceutical.

Pharma Division

The world market for anti-infectious drugs is highly competitive and producers in this market include some of the largest pharmaceutical companies, including Pfizer Inc., GlaxoSmithKline, Schering-Plough, Abbott Laboratories and Sandoz.

There are numerous pharmaceutical manufacturers of anti-infectious drugs in China. The top four producers are Harbin Pharmaceutical Group Holding Co., Ltd., Shijiazhuang Pharmaceutical Group Co., Ltd., Shanghai Pharmaceutical Co., Ltd. and North China Pharmaceutical Co., Ltd. All these companies or their affiliates are publicly traded companies listed on the Shanghai or Hong Kong stock exchanges. All of these competitors are substantially larger than the Company as they were all state-owned enterprises before becoming public and some of them are still partially owned by the Chinese government. These larger competitors may enjoy the benefits of economies of scale and therefore be able to afford to sell competing products at lower prices than the Company. This may have an adverse effect on the Company's profitability.

Biotech Division

We have estimated that the world market for EPO to be approximately \$9 billion in annual sales and believe the market is growing. The market is dominated by three firms: Amgen Inc. of Thousand Oaks, California; Ortho Pharmaceutical Corp., a subsidiary of Johnson & Johnson, Inc. of New Brunswick, New Jersey; and Kirin Brewery Company Limited of Japan. EPO is marketed by Amgen as "Epogen," by Johnson & Johnson as "Procrit/Epex" and by Kirin as "Espo." A fourth participant in the international EPO market is Roche Holding AG of Switzerland, which markets an EPO drug with a different heritage.

Amgen was granted United States rights to market EPO under a licensing agreement with Kirin-Amgen, Inc., a joint venture between Kirin and Amgen that was established in 1984. Johnson & Johnson acquired the rights to EPO from Kirin-Amgen for all treatments except kidney dialysis in the United States and for all uses outside the United States in 1985. Both Amgen and Kirin individually manufacture and market EPO for China and Japan. These international drug companies all have more financial resources than we do.

In addition to these international drug companies, we are competing with existing and potential Chinese producers such as Sunshine SS Pharma and Sinogen. Many of our competitors may have greater financial, technical and manufacturing resources than we have. These resources would allow our competitors to respond more quickly to new or emerging advances in the drug industry and to devote greater resources to the development, promotion and sale of their products.

Potential competition in the EPO market includes other products or technologies that are successful in treating anemia. Amgen has sole right to Novel Erythropoiesis Stimulating Protein, a second-generation EPO molecule that will pose serious competition to the existing products because it offers the possibility of less frequent dosing (i.e., once a week rather than three times a week).

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

In addition, current and potential competitors may make strategic acquisitions or establish cooperative relationships among themselves or with third parties that could increase their ability to reach customers in the Chinese market. Such existing and future competition could affect our ability to penetrate the Chinese market and generate sales. No assurances can be given that we will be able to compete successfully against current and future competitors, and any failure to do so would have a material adverse effect on our business.

Intellectual Property, Government Approvals and Regulations

Intellectual Property

The Company, through its subsidiary, Shanxi Weiqida, has 15 registered trademarks and has applied for registration of another 19 trademarks in China. The Company has not applied to patent any of its products, techniques or procedures.

Other than obtaining product protection from the SFDA for each of the new products developed, The Company does not have any other measures to prevent any infringement of its intellectual property rights. Currently, three of the Company's manufactured pharmaceutical products, is entitled to protection with which the SFDA will not issue additional drug permits other than those already issued during the protection period. The following table illustrates our products with protection period and their respective expiration dates.

Product Name	Expiration
Levofloxacin Hydrochloride for Injection	May 2006
Sulbactam Sodium Amoxicillin Sodium for Injection	April 2006
Mezlocillin Sodium - Sulbactam Sodium for Injection	December 2009

Regulation of the Chinese Pharmaceutical Industry

The modernization of regulations for the pharmaceutical industry is relatively new in China and the manner and extent to which this industry is regulated will continue to evolve. As a pharmaceutical company, Shanxi Weiqida is subject to the Pharmaceutical Administrative Law, which governs the licensing, manufacture, marketing and distribution of pharmaceutical products in China. Additionally, Shanxi Weiqida is subject to varying degrees of regulation by governmental agencies in China.

Principal supervisory authority in the industry. SFDA is the principal supervisory authority in the pharmaceutical industry in China. It was established in March 2003 on the basis of the former State Drug Administration of China, which was established in March 1998. The SFDA is responsible for the administrative and technological supervision of the research, production and trading of pharmaceutical products and the consolidated supervision of the safety management of food, health care and cosmetic products.

Certificates, permits and licenses for pharmaceutical manufacturing and trading enterprises. A pharmaceutical production enterprise or pharmaceutical trading enterprise must apply for the relevant permit from the relevant regulatory department in China. The Industry and Commerce Administration Department will issue a "business license" only after the pharmaceutical regulatory department has considered the application and approved the issue of a "pharmaceutical production permit" or "pharmaceutical trading permit". Such permits are valid for a period of five years and application for renewal must be made six months prior to its expiry date. A new permit will be issued after reassessment, examination and approval by the relevant pharmaceutical regulatory department.

Good Manufacturing Practices ("GMP"). GMP is a set of standards in respect of quality management of the manufacturing of pharmaceutical products which is promoted by the World Health Organization ("WHO"). These are applicable to the entire pharmaceutical production process and the key working procedures for the production of raw materials which affect the quality of finished medicine products. Many countries have formulated their own requirements for GMP based on the GMP promoted by WHO. The Administration Center of Pharmaceutical Certification of the SFDA is responsible for pharmaceutical GMP certification in China. A GMP certificate is valid for a term of five years and application for renewal has to be submitted three months prior to its expiration date.

Registration of pharmaceutical products. All pharmaceutical products proposed to be sold in China (including previously unapproved drugs, changes in the form or method of administration of previously approved drugs and imported pharmaceutical products) are required to be registered and obtain an approved pharmaceutical number granted by the SFDA. The procedures for applying for registration of pharmaceutical products can be generally divided into the following stages:

- o after completion of the pre-clinical research of the new medicine, application for registration of the new medicine must be submitted to the drug regulatory authorities at the provincial level for review. The drug regulatory authorities at the provincial level, after completion of its review, may submit its opinion and report to the SFDA for review;
- o if all the requirements are complied with, the SFDA will issue a notice of acceptance and proceed with its assessment on whether to grant the approval for conducting the clinical research on the new medicine;
- o after obtaining the approval for conducting the clinical research by the SFDA, the applicant may proceed with the relevant clinical research (which is generally divided into three phases) at institutions with the appropriate qualifications;
- o after completion of the relevant clinical research, the applicant must submit its clinical research report together with the relevant supporting documents to the drug regulatory authorities at the provincial level and provide the raw materials of the new medicine to the China Examination Bureau of Pharmaceutical and Biological Products (the "China Examination Bureau");
- o the China Examination Bureau will arrange for the conduct of examination of the raw materials supplied by the relevant medicine examination institutes which will then issue the examination result report;
- o the drug regulatory authorities at the provincial level must then review the relevant documents, conduct site inspection, exam samples and, thereafter, submit its opinion, inspection reports and other application materials to the SFDA for review; and
- o if all the regulations are complied with, a certificate of new medicine and a pharmaceutical approval number (if the applicant has a valid Pharmaceutical Products Production Permit and the requisite production conditions for the new medicine) will be granted by the SFDA.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Prescription medicines and over-the-counter medicines. Prescription medicines must be dispensed, purchased and taken with the prescription of practicing doctors or assistant doctors. Purchase of over-the-counter medicines do not require doctors' prescriptions and can be dispensed, purchased and taken by users. The SFDA is responsible for the selection, approval, publication, and revision of the over-the-counter medicine catalogue.

14

Wholesalers of prescription and over-the-counter medicines and retailers of prescription and over-the-counter type A medicines must hold a "pharmaceutical trading enterprise permit". Commercial entities may engage in the retail of over-the-counter type B medicines subject to the approval of the provincial pharmaceutical regulatory authorities or their delegated bureaus. Prescription medicines may be advertised only in medical journals and over-the-counter medicines may be advertised in the mass media.

Import and export restriction. Imported pharmaceutical products are required to meet certain safety and quality standards set by the Chinese government. In addition, these products should have been approved for sale in the country or region where they are manufactured. If the products are not approved in the foreign countries, they can be imported only subject to the approval from the SFDA. The export of pharmaceutical products when there is shortage of supply in China may be restricted or prohibited.

Price control. In July 2000, in order to enhance market competition of the pharmaceutical industry and to reduce medical expenses, the former State Development and Planning Commission of the PRC promulgated a new policy in respect of reforming the price control of pharmaceutical products in China. According to the policy, the price of pharmaceutical products is subject to the control of the price supervising bureau at state and provincial levels. The bureau generally classifies pharmaceutical products into two groups: (1) government-pricing pharmaceutical products; and (2) market-pricing pharmaceutical products.

Pharmaceutical products where prices are determined by National Development and Reform Commission of the PRC are limited to Category A pharmaceutical products listed in Medicine Catalogue of National Basic Medical Insurance and pharmaceutical products with monopolistic attributes (including anaesthetic medicines, certain type of psychiatric medicines, vaccines and contraceptive drugs). The price of Category B pharmaceutical products listed in the Medicine Catalogue of National Basic Medical Insurance are determined by the price supervising bureau at the provincial level according to the price determination policies adopted by the Central Government.

On November 21, 2000, the former State Development and Planning Commission of the PRC promulgated Notice Regarding Rules on Application for Approval for the Prices of Pharmaceutical Products set by the PRC Government, stating that:

(i) for all pharmaceutical products first launched in China as listed in the price index of the State Development and Planning Commission of China, drug manufacturing enterprises are required to submit their price-setting applications to the price supervising bureau at the provincial level. The provincial price supervising bureau would then transfer such applications to the former State Development and Planning Commission of the PRC after review for further approval;

(ii) for all new pharmaceutical products first launched in China as listed in the price index of the provincial government, drug manufacturing enterprises are required to submit their price-setting applications to price supervising bureau at the provincial level;

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

(iii) for the patented pharmaceutical products, Categories 1 and 2 new pharmaceutical products not listed in Medicine Catalogue of National Basic Medical Insurance, after trial production in China, drug manufacturing enterprises are required to submit their price-setting applications to the price supervising bureau at the provincial level for preliminary approval when they make applications for formal production. Then the provincial price supervising bureau would then transfer such applications to the former State Development and Planning Commission of the PRC to determine the price;

(iv) for the patented pharmaceutical products, Categories 1 and 2 pharmaceutical products not listed in Medicine Catalogue of National Basic Medical Insurance, which are not required to be carried out trial production in China, drug manufacturing enterprises are required to submit their price-setting

15

applications to the price supervising bureau at the provincial level for approval after one year from obtaining of the production approval or the first import permit. Then the provincial price supervising bureau would then transfer such applications to the Economic Planning Commission of China for further approval; and

(v) for all pharmaceutical products currently sold in China market as listed in The Price Index of the Provincial and the State Development and Planning Commission of China, before new prices are set by the relevant price supervising authorities according to the market survey information, drug manufacturing enterprises can sell their products at the then prevailing price.

Approximately 46 out of the 89 products from the Pharma Division and Biotech Division of the Company, accounting for approximately 34% of its 2004 sales and 27 % of its sales of 2005, are subject to government imposed retail price controls in China. If manufacturing costs increase for products of the Company that are subject to price ceilings, and the retail price for those products is not adjusted upwards, the Company's profitability may be adversely affected.

Reimbursement. Only those drugs that appear on the provincial and municipal reimbursement lists are covered by the national medical insurance system, which may favor locally-manufactured products as they may be lower cost alternatives. The State Development Planning Commission of China has announced its intention to re-examine the pricing of drugs in China.

Product liability. Product liability claims may arise if harmful products are sold to members of the public or if there are any alleged harmful effects from the consumption of the products. Under current Chinese laws, manufacturers and vendors of defective products in China may incur civil and criminal liability for loss and injury caused by such products.

Research and Development.

Dragon's research and development activities mainly focus on two objectives: the development of generic drugs, including new presentations and dosage forms of already approved generic drugs, and the improvement of product quality and production technology. In order to fulfill those objectives, the research and development department utilizes both internal and external resources, such as cooperation with universities and other research laboratories. From time to time the Company, through its subsidiary, has established on-going collaborations on product development and production techniques development with external research institutes such as universities and other research laboratories. However, the Company has no long term

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

arrangements with these universities

Total expenditures on research and development for the years ended December 31, 2005 and 2004 were \$208,414 and \$193,188, respectively.

Geographical Breakdown.

81% and 95% of the Company's revenues for the year ended December 31, 2005 and 2004, respectively, were derived from customers located in China. The Company had sales of \$6,593,391 and \$644,100 in the Chemical and Biotech Divisions to customers in India, representing 13% of the Company's revenues for the year ended December 31, 2005. 99% and 100%, respectively, of the Company's assets at December 31, 2005 and 2004 were located in China.

Suppliers

The Company uses many different raw materials in the manufacturing process of its pharmaceutical products. The Company mainly sources its raw materials in China, but also purchases raw materials from some overseas markets. The Company has not entered into any supply contracts with any of its suppliers which exceed

16

twelve months. During 2005, the Company did not experience any significant difficulties in sourcing raw materials and the management of the Company does not anticipate that, if required, it will face any material difficulties in sourcing its raw materials from alternative suppliers.

Customers

For the Chemical division, our customers are pharmaceutical formulation companies that purchase our API and pharmaceutical intermediate for further processing and formulation into finished products.

For the Pharma division and the Chinese customers for the Biotech division, our customers are hospitals in China which purchase our products through their logistic partners. Hospitals, in turn, sells our products to patients.

For the international customers of the Biotech division, our customers are our licensees which purchase the products from us and then resell it to hospitals.

Employees

As of December 31, 2005, the Company has 11 in North America and 1,784 employees in China. None of our workforce is a member of a union and there were no labor disputes.

Business Risks Associated with Dragon Pharmaceutical

An investment in our common stock involves a high degree of risks. Before you invest, you should carefully consider the risks described below. If any of the following risks occur, our financial condition or results of operations could be materially harmed.

Certain Officers and Directors have significant control.

Messrs. Han and Weng and Ms. Liu, who are officers and/or Directors, own, in the aggregate, 70.78% of our issued and outstanding shares of common stock. As a result, these shareholders will be able to control certain corporate

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

governance matters requiring shareholders' approval. Such matters may include the approval of significant corporate transactions requiring a majority vote without seeking other shareholders' approval. They will also have the ability to control other matters requiring shareholder approval including our election of directors which could result in the entrenchment of management.

The acquisition may fail to achieve the expected benefits.

We have completed the acquisition of Oriental Wave in January 12, 2005 in an effort to obtain additional sales and operating efficiencies, among other benefits. These expected benefits may not be achieved. Whether we ultimately realize these benefits will depend on a number of factors, many of which are outside our control including our success in integrating Oriental Wave's operations, technological changes, the impact of competitive forces, and other general market conditions or economic factors specific to the pharmaceutical industry in general. Even if we are able to integrate our respective operations and if economic conditions remain stable, there can be no assurance that the anticipated benefits will ever be achieved. The failure to achieve such benefits could have a material adverse effect on the business, results of operations and financial condition of the combined company.

Dragon has a negative working capital and we must restructure our short-term loans.

As of December 31, 2005, Dragon had a negative working capital of \$13.31 million, including short-term notes due of \$13.48 million. As a result, Dragon must, during the upcoming twelve months, negotiate with its banks to restructure

17

or renew its notes. Assuming that Dragon is successful in renegotiating its notes and that vendors continue to work with Dragon as to their accounts payables, Dragon believes that it will be able to continue to fund its operations from product sales for the near future. However, this negative working capital may limit Dragon's growth, since the majority of its earnings will be used to pay accounts payable and existing debts. Further, if Dragon is unsuccessful in restructuring and renewing its notes or if vendors demand immediate payment, these actions will adversely affect operations and may require Dragon to sell certain assets to pay off liabilities.

Dragon relies heavily on the sale of a few products.

Dragon's top five products for 2004 were Amoxicillin Sulbactam for injection, Mezlocillin for injection, Ampicillin Cloxacillin for injection, Metronidazole for injection, and clavulanic acid, while the top five products for 2005 were 7-ACA, EPO, clavulanic acid, Mezlocillin, and Amoxicillin Sulbactam. The top five products sold by Dragon amounted to approximately \$18.83 million and \$37.33 million of its sales during 2004 and 2005, respectively, representing approximately 65% and 66% of Dragon's overall sales for those periods. Although we do not anticipate that there will be a material change in demand for these products, a change in demand for these products due to world competition, market forces or other factors outside of its control, could adversely affect our sales and net income.

Shanxi Weiqida is required to contribute a portion of its net income to Reserve Funds which may not be distributed.

By law, Shanxi Weiqida is required to contribute at least 10% of its after tax net income (as determined in accordance with Chinese GAAP) into a reserve fund until the reserve is equal to 50% of Shanxi Weiqida's registered capital, a further percentage of its after tax net income, as determined by Shanxi

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Weiqida's Board of Directors, into a staff welfare fund, and into an enterprise expansion fund if determined by the Board of Directors. The reserve fund and enterprise expansion fund are recorded as part of shareholders' equity but are not available for distribution to shareholders other than in the case of liquidation, while the staff welfare fund is recorded as a liability, and is not available for distribution to shareholders. As a result of this requirement, the amount of net income available for distribution to shareholders will be limited.

We intend to raise additional capital through the issuance of equity securities that will dilute the ownership other shareholders.

We intend to raise additional capital through the issuance of our equity securities to finance our growth and reduce short-term debt and other liabilities. No assurance can be given that we will be successful in our efforts. Further the issuance of equity securities will reduce other shareholders' ownership in us.

We may be subject to product liability claims in the future that could harm our business and reputation.

Product liability claims may arise if harmful products are sold to members of the public or if there are any alleged harmful effects from the consumption of our products. Under current Chinese laws, manufacturers and vendors of defective products in China may incur liability for loss and injury caused by such products, including having their business licenses revoked and facing criminal liability. Consistent with industry practice in China, Shanxi Weiqida does not carry liability insurance coverage. Should any product liability claim be brought against us, there is no assurance that it would not have an adverse impact on our business, profitability or business reputation.

18

We will be dependent upon the services of Mr. Han

Mr. Yanlin Han is our largest shareholder and serves as our CEO and Chairman of the Board. As a result, our operations will be dependent on Mr. Han who has been the driving force behind the Company. If something happens to Mr. Han, this could divert management's time and attention and adversely affect our ability to conduct the combined business effectively.

Dragon relies heavily on the China market and changes in the market could harm our business

During 2004 and 2005, 95% and 81% of Dragon's sales, respectively, were derived from China. It is anticipated that Dragon's products in China will continue to represent a significant portion of sales in the near future. As a result of its reliance on the China market, the operating results and financial performance of Dragon is completed could be affected by any adverse changes in economic, political and social conditions in China. For example, if legislative proposals for pharmaceutical product pricing, reimbursement levels, approval criteria or manufacturing requirements should be proposed and adopted, such new legislation or regulatory requirements may have a material adverse effect on our financial condition, results of operations or cash flows. In addition, we will be subject to varying degrees of regulation and licensing by governmental agencies in China. At this time, we are unaware of any China legislative proposals that could adversely affect our business. There can be no assurance that future regulatory, judicial and legislative changes will not have a material adverse effect on Dragon, that regulators or third parties will not raise material issues with regard to compliance or non-compliance with applicable laws or regulations or that any changes in applicable laws or regulations will not have a material adverse effect on Shanxi Weiqida or our

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

operations.

Certain products are subject to price controls and if the related manufacturing costs increase, our potential profits may be harmed.

In July 2000, in an effort to enhance market competition in the pharmaceutical industry and to reduce medical expenses, the former State Development and Planning Commission of the People's Republic of China promulgated a new policy to reform the price control of pharmaceutical products in China. According to the policy, the price of pharmaceutical products and biotech products is subject to the control by government bureaus at state and provincial levels. In the event that the sale prices of our products are limited by government bureaus at the state and provincial levels, this may have an adverse effect on our net income, especially if our costs associated with those products increase. Approximately 46 out of the 89 products from the Pharma Division and Biotech Division of the Company, accounting for approximately 34% of 2004 sales and 27% of 2005 sales, are subject to governmental imposed retail price controls in China. If manufacturing costs increase for products that are subject to price ceilings, and the retail price for those products is not adjusted upwards, our profitability may be adversely affected.

Dragon is required to maintain compliance with GMP standards.

All pharmaceutical manufacturers in China, including Shanxi Weiqida, a subsidiary of Dragon, are required to comply with certain Good Manufacturing Practice, or GMP, standards by certain time limits and, if not met, their pharmaceutical manufacturing enterprise permits will be revoked or they will not be renewed and accordingly production will have to be terminated. A GMP certificate is valid for five years from the issuance date of such certificate.

Shanxi Weiqida has been accredited with all GMP certificates it requires for its production facilities. Shanxi Weiqida's GMP certificate for the Pharma division facility will expire and is subject to recertification in August 2008, the GMP certificate for the Clavulanic acid facility of the Chemical division will expire and is subject to recertification in January 2009, and the GMP certificate for the EPO and freeze-dry facility of the Biotech division will expire and is subject to recertification in December 2010. The standard of compliance required in connection with GMP certificates may change from time to

19

time, which may give rise to substantial compliance burdens and increase Shanxi Weiqida's costs in the future. If the recertification of any required GMP-related status is not granted, the relevant operations of Shanxi Weiqida may have to be terminated which in turn would have an adverse impact on our profitability.

Currency conversion and exchange control could adversely effect our operations and profitability.

The sales and expenses of Shanxi Weiqida are substantially settled in Renminbi, or RMB, however, our financial statements are reported in U.S. dollars. Accordingly, our net income, the value of our assets and our ability to pay dividends, if any, in U.S. dollars may be adversely affected by negative changes in the exchange rate of RMB against the U.S. dollar or other currencies.

Major reforms have been introduced to the foreign exchange control system of China. In 1994, the previous dual exchange rate system for RMB was abolished and a unified floating exchange rate system, based largely on supply and demand, was introduced. Since December 1996, under the rules of International Monetary Fund, or IMF, China has provided a free exchange of current accounts, while

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

capital accounts have been subject to foreign exchange control. Foreign exchange transactions under a capital account, including foreign currency-denominated borrowings from foreign banks and principal payments in respect of foreign currency-denominated obligations, continue to be subject to significant foreign exchange controls and require the approval of the State Administration of Foreign Exchange. However, the payment in and transfer of foreign exchange for current international transactions, such as the payment of dividends or other distributions to shareholders, is deemed a current account and therefore is not subject to Chinese government controls or restrictions. Although China's commitment to IMF is unlikely to change, limitations on foreign exchange could affect our ability to obtain foreign exchange for capital expenditures and we continue to be exposed to negative changes in exchange rates.

On July 22, 2005, the Chinese government decided to no longer peg the value of the Renminbi to the US dollar but rather to a basket of currencies of its largest trading partners. The result was an appreciation of the Renminbi of approximately 2% against the value of the US dollar (and a further 0.5% increase over the balance of the year). The effect of the revaluation was an increase in the assets, liabilities, revenues and expenses of the Company and a foreign currency gain included in comprehensive income.

Dragon does not have patent protection and is subject to substantial competition.

Dragon competes in the generic drug segment of the pharmaceutical industry and has no patent protection for any of its products. Many pharmaceutical companies compete in the same market segment with similar products or products having comparable medicinal applications or therapeutic effects which may be used as direct substitutes for Dragon's products. Further, many of these competitors are larger and have greater resources and market presence than Dragon. Larger competitors may, as a result of economies of scale, be able to afford to sell competing products at lower prices than Dragon. This will have an adverse effect on Dragon's profitability. These competitors include Harbin Pharmaceutical Group Holding Co. Ltd, Shijiazhuang Pharmaceutical Group Co., Shanghai Pharmaceutical Co., Ltd. and North China Pharmaceutical Co., Ltd.. As a result of the lack of patent protection, competitors with potential substitutes could launch similar products in the market with their prices analogous with or lower than those manufactured and sold by Dragon. Further, the lack of patent protection could also attract an even greater number of competitors who believe they can develop products that are substantially similar to those of Dragon at a lower cost.

Expansion into overseas markets could pose additional risks.

Dragon plans to expand sales of products from its Pharma and Chemical Divisions into overseas markets including developing and developed countries. These markets are untested for Dragon's products and Dragon, as well as the combined company after the acquisition, faces risks in expanding the business overseas, which include differences in regulatory product testing requirements,

20

patent protection, taxation policy, legal systems and rules, marketing costs, fluctuations in currency exchange rates and changes in political and economic conditions.

Chinese economic planning could negatively impact the pharmaceutical market in which our products are sold.

China has a long history of a planned economy and is still subject to plans formulated by the Central Chinese government. In recent years, the Chinese

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

government has introduced economic reforms aimed at transforming the Chinese economy from a planned economy into a market economy with socialist characteristics. These economic reforms allow greater utilization of market forces in the allocation of resources and greater autonomy for enterprises in their operations. However, many rules and regulations implemented by the Chinese government are still at an early stage of development and further refinements and amendments are necessary to enable the economic system to develop into a more market oriented form. No assurance can be given that any change in economic conditions as a result of the economic reform and macroeconomic measures adopted by the Chinese government will have a positive impact on the Chinese economic development or its pharmaceutical sector, which is the market where our products are sold. At the same time, there can be no assurance that such measures will be consistent and effective or that we will benefit from or will be able to capitalize on all such reforms.

ITEM 2. DESCRIPTION OF PROPERTY

Our corporate administrative offices were located at 1055 West Hastings, Suite 1900, Vancouver, British Columbia, Canada V6E 2E9. The Company leases the 6,432 square foot premise for an amount escalating from CDN\$200,000 to CDN\$230,000 (approximately \$155,000 to \$178,000) per annum until March 31, 2007.

Subsequent to December 31, 2005, the Company subleased its old office space and entered into a new operating lease agreement in Vancouver at Suite 310, 650 West Georgia street, Vancouver, British Columbia, Canada covering 2,222 square feet for approximately CDN\$73,000 (\$60,000) per annum until March 31, 2011. The Company anticipates recovering \$124,000 and \$41,000 during fiscal 2006 and 2007, respectively, under its sublease agreement.

Company's manufacturing facility of the Pharma Division with a total of approximately 258,300 square feet is located in the Datong Economic and Technology Development Zone in Datong City, Shanxi Province of China. This fully-integrated facility includes a headquarters building, three production workshops (formulation drugs, sterilized bulk drugs and powder for injections) that house a total of eight production lines (four in the formulations workshop, one in the sterilized bulk drugs workshop and three in the powder for injections workshop), utility infrastructure, quality assurance and quality control and warehouse area. The Company holds the land use right for this facility until June 2047.

Company's Chemical facility and the new facility for the Biotech Division are also located in Datong City. This campus, with a total area of approximately 947,200 square feet, houses the Clavulanic acid production facility, power, boiler, steam and water facilities and 7-ACA production facility and EPO production facility. The land use right for this campus expires in August 2053.

The Company's biotech facility was originally located in Nanjing, China but was closed in August, 2005 and relocated to the campus that houses the Chemical division.

21

ITEM 3. LEGAL PROCEEDINGS

Dragon Pharmaceutical Inc. v. Longbin Liu, Supreme Court of British Columbia, Canada, No. S036057, filed November 10, 2003. On November 2003, we filed a complaint against our former Director and Chairman for payment of \$3,500,000, plus interest calculated at 6% per annum, due on September 5, 2003, pursuant to the terms of the Acquisition Agreement related to Hepatitis B Vaccine Project entered into by us and Dr. Liu on October 6, 2000, as amended on June 5, 2001.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

On April 4, 2004, we entered into a comprehensive settlement with Dr. Liu and Novagen, a company controlled by Dr. Liu, to settle the amount owed to us by Dr. Liu as a result of his acquisition of the Hepatitis B Project. The settlement agreement provides that the Hepatitis B Project and Patent and Project Development agreements dated January 14, 2002, as amended, have been cancelled. Further, pursuant to the settlement agreement, the G-CSF, Insulin and Hepatitis B Projects, including rights of ownership and development obligations would revert to Dr. Liu.

In exchange, Dr Liu agreed to pay us \$3,710,000 in principal and interest owing under the Hepatitis B Project as well as reimburse us \$1,330,000 that had been paid previously under the Patent and Project Development agreements. All amounts were due on December 31, 2004 and Dr. Liu has agreed to provide 2,600,000 common shares of the Company, to be held in escrow, as security for the amounts owing. The warrants granted to Dr. Liu under the Patent Development agreement were also cancelled. Pursuant to the settlement agreement 2,231,000 common shares of the Company were placed in escrow. Finally, as part of the settlement agreement each party agreed to mutually release the other party for any prior claims against each other.

Dr. Liu has failed to pay us the amounts due on December 31, 2004. We have foreclosed on Dr. Liu's 2,231,000 shares of common stock that were pledged as security and will cancel the shares. After foreclosing on such shares, the balance owe to us by Dr. Liu amounts to approximately \$2.48 million and we are currently considering what further actions we may take against Dr. Liu.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted for shareholders vote during the fourth quarter.

PART II

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

Our common stock began quotation on the OTC Bulletin Board on October 9, 1998 under the symbol "DRUG". In addition, our shares of common stock are listed on the Toronto Stock Exchange under the symbol "DDD" and are quoted on the Berlin-Bremen Exchange, the Frankfurt Exchange and the XETRA Exchange under the symbol "DRP". The OTC Bulletin Board represents our primary market representing approximately 92.4% of our trading volume. Our common stock being quoted and traded on the Berlin-Bremen Exchange, Frankfurt Exchange and XETRA Exchange are without the Company's prior knowledge. The following quotations reflect the high and low bids for our common stock on a quarterly basis for the past two fiscal years as quoted on the OTC Bulletin Board. These quotations are based on inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.

22

Quarter Ended	Common Stock	
	High	Low
December 31, 2005	\$0.85	\$0.51
September 30, 2005	\$1.00	\$0.69
June 30, 2005	\$1.03	\$0.75
March 31, 2005	\$1.26	\$0.80
December 31, 2004	\$1.41	\$0.80

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

September 30, 2004	\$1.01	\$0.83
June 30, 2004	\$1.10	\$0.67
March 31, 2004	\$1.22	\$0.81

Holders

As of March 15, 2006, there were 74 registered holders of our common stock. As many of the shares of common stock are held in street name, there may be additional beneficial holders of our common stock.

Dividend Policy

We have paid no dividends on our common stock since our inception and may not do so in the future. For the foreseeable future, we expect earnings, if any, will be retained to finance the growth of the Company.

ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Except for statements of historical facts, this section contains forward-looking statements involving risks and uncertainties. You can identify these statements by forward-looking words including "believes," "considers," "intends," "expects," "may," "will," "should," "forecast," or "anticipates," or the negative equivalents of those words or comparable terminology, and by discussions of strategies that involve risks and uncertainties. Forward-looking statements are not guarantees of our future performance or results, and our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under "Risk Factors." This section should be read in conjunction with our consolidated financial statements.

The following discusses the Company's financial condition and results of operations for the years ended December 31, 2005 and 2004 based upon the Company's consolidated financial statements which have been prepared in accordance with the United States generally accepted accounting principles. Due to the fact that Dragon's acquisition of Oriental Wave Holding Limited ("Oriental Wave") on January 12, 2005 is deemed to be a reverse-take-over transaction, the following discussion reflects the Company's results of operations for the year ended December 31, 2005, including the results of Oriental Wave for the full year and the results of Dragon's biotech business for the period of January 12, 2005 to December 31, 2005. Comparatively, the results of operations for the year ended December 31, 2004 only reflected the Pharma and Chemical businesses of Oriental Wave.

Results of Operations for the Fiscal Years Ended December 31, 2005 and 2004

Sales for the year ended December 31, 2005 increased 94% to \$56.24 million from \$29.02 million for the same period in 2004. \$45.63 million or approximately 81% of the sales for the year ended December 31, 2005 were generated from the sales of products in the Chinese market, and the remaining \$10.61 million or

approximately 19% were generated from the sales of products in the international markets (outside of China) 95% of the sales for the year ended December 31, 2004 were generated from the sale of products in the Chinese market. In the year ended December 31, 2005, \$25.08 million or approximately 45% of the sales were from the Pharma Division, \$27.33 million or 48% of sales were from the Chemical Division, and \$3.83 million or 7% of sales were from the Biotech Division. For the same period in 2004, 85% of sales were from the Pharma Division and 15% of sales were from the Chemical Division which commenced operation on January 1, 2004. The increase in sales for the year ended December 31, 2005 as compared to

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

the prior year was primarily due to increase in sales from the Chemical and Biotech Division.

Cost of sales for the year ended December 31, 2005 was \$42.30 million compared to \$16.14 million for the same period of 2004. The cost of sales is attributed to the production costs of Dragon's pharmaceutical products with the increase in the cost of sales related to the growth in products and sales in the Chemical Division. Gross profit and gross margin for the year ended December 31, 2005 were \$13.95 million and 25% compared to \$12.88 million and 44% for the same period of 2004. The decrease in gross margin was mainly due to a change in the product mix from the previous year with the significant increase in the Chemical Division revenues. The Chemical Division, whose facilities were brand new in 2004 and was ramping up production in 2005 which incurs higher production and operation cost, especially depreciation expenses, increased the cost of sales significantly during the year ended December 31, 2005.

Divisional Revenues and Gross Margin Analysis

The Company's businesses are organized under three business divisions: the Chemical Division, the Pharma Division and the Biotech Division.

Chemical Division

The Chemical Division's revenues for the year ended December 31, 2005 were \$27.33 million, representing a 543% increase from the revenues of \$4.25 million during the same period in 2004. The increase is due to the introduction of 7-ACA and the expansion of Clavulanic acid sales outside China. The Chemical division was new in 2004 as only the Clavulanic acid facility had started production and the sales during 2004 were only made to Chinese customers. Since then, the Company started the production of the 7-ACA production facility and the Company has received export permits to sell three clavulanic acid products to the Indian market.

The Chemical Division's gross margin for the year ended December 31, 2005 was 4% compared to 5% for the year ended December 31, 2004. The gross margin for the division was low as the Company has increased and expanded the infrastructure, and the fixed manufacturing costs associated, and was in the process of ramping up production to cost efficient levels. The initial Chemical Division production in 2004 was limited to Clavulanic acid and was produced with older, smaller scale production infrastructure. The Company constructed the new production infrastructure (power, steam, purified water supply and water treatment) during 2004 as the old production infrastructure was insufficient to produce the amount of Clavulanic acid and 7-ACA desired. The new facilities have greatly increased production capacity but also have significantly higher fixed costs in the form of depreciation cost (\$4.31 million and \$2.03 million for the years ended December 31, 2005 and 2004, respectively) of the new facilities constructed and overhead of the utilities costs to power the new facilities. These fixed costs are expected to fall significantly, on a percentage basis, when the anticipated production levels are achieved

Pharma Division

The Pharma Division's revenues for the year ended December 31, 2005 were \$25.08 million, accounting for 45% of the total revenues of the Company. Comparatively, Pharma Division's revenues were \$24.77 million for the same period in 2004, contributing 85% of the total revenues of the Company. The lowering of percentage of revenues from the Pharma division to the Company was

due to the tremendous growth of the brand new Chemical division achieved during

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

2005. The overall gross margin for the division for the year ended December 31, 2005 was 40% as compared to 51% for the same period of 2004. The lowering of gross profit was mainly due to the price control by the government as well as a change in sales model for Pharma Division products. The company implemented a new sales model for Pharma Division products to recognize selling prices and gross profits lower than those under the original sales model but, under the new sales model, the Company also lowers the selling expenses with a faster payment collection cycle which will be reflected in lower account receivables.

Biotech Division

The Biotech Division's revenues for the year ended December 31, 2005 were \$3.83 million representing 7% of the Company's revenues for the year. Gross margin for the year ended December 31, 2005 was at 73%. The acquisition of Oriental Wave by Dragon completed on January 12, 2005 was accounted for as a reverse-take-over transaction. As a result, only revenues from the Biotech Division from January 12, 2005 to December 31, 2005 were included in the Company's revenues for 2005 and no revenues from the Biotech Division were included in the 2004 financials.

On a pro-forma basis (assuming the reverse-take-over had occurred at the beginning of the year), for the year ended December 31, 2005, Biotech Division's revenues were \$3.97 million representing a 7% increase from the 2004 level. The increase in total sales for the year ended December 31, 2005 came from an increase in the sales in the Chinese market. .

Biotech Division's pro-forma gross margin for the year ended December 31, 2005 was 73% compared to 58% for the same period of 2004. The 2004 margin was unusually low as the Company wrote-down the cost (approximately \$400,000) of bulk EPO produced from the bioreactor cell line as the product could only be sold for research purposes.

Other Income/Expense During the year ended December 31, 2005, the Company recognized a net other expense of \$0.62 million. This amount primarily consisted of \$1.33 million of interest expense and \$0.26 million in acquired research and development costs that were written off during the year and was partially offset by \$0.89 million from funds released by a Chinese Government Liquidator related to Datong Pharmaceutical. The other expense for the year ended December 31, 2004 was 0.21 million.

Expenses. Total operating expenses were \$12.60 million for the year ended December 31, 2005. The major category of operating expenses was General and Administration expenses of \$6.67 million, Selling expense of \$4.84 million, and Depreciation and Amortization expenses of \$1.09 million. Total operating expenses were \$5.86 million for the year ended December 31, 2004 with the major expenses being General and Administration expenses of \$1.91 million, Selling expense of \$3.67 million, and Depreciation and Amortization expenses of \$0.28 million. During the year ended December 31, 2005, the General and Administration expenses included \$2.40 million for salaries, compensation and benefits, \$0.72 million for travel expenses, \$0.48 for professional fees, \$0.43 million for rent and \$0.96 for product testing costs compared to \$0.25 million for salaries, compensation and benefits and \$0.46 million for travel expenses, and \$0.30 million for professional fees for the same period in 2004.

The increase in operating expenses of \$6.74 million for the year ended December 31, 2005 as compared to the same period for the prior year reflects the increased overhead related to the operations of both the Pharma and Chemical Divisions in 2005 (compared to just the Pharma Division and one of the two facilities of the Chemical Division in 2004) and the addition of the Biotech operations and the head office in Vancouver.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Net Income. Dragon had a net income of \$0.18 million for the year ended December 31, 2005 compared to a net income of \$6.36 million for the same period in 2004.

Comprehensive Income. Dragon had foreign currency translation income of \$0.75 million as other comprehensive income for the year ended December 31, 2005. The foreign currency translation income results from translation of the financial statements expressed in RMB to United States Dollar.

On July 22, 2005, the Chinese government decided to no longer peg the value of the Renminbi to the US dollar but rather to a basket of currencies of its largest trading partners. The result was an appreciation of the Renminbi of approximately 2% against the value of the US dollar (and a further 0.5% increase over the balance of the year). The effect of the revaluation was an increase in the assets, liabilities, revenues and expenses of the Company and a foreign currency gain included in comprehensive income.

Basic Net Income Per Share. Dragon's net income per share has been computed by dividing the net income for the period by the weighted average number of shares outstanding during the same period. Net income per share for the year ended December 31, 2005 was \$0.00 per share and \$0.14 for the year ended December 31, 2004. The weighted average number of shares outstanding during year ended December 31, 2005 was 62,273,862 and was 44,502,004 shares during year ended December 31, 2004. The outstanding common stock options have no significant dilutive effect on the weighted average number of shares outstanding.

Dividends of the PRC subsidiary may only be distributed after allowance has been made for i) recovery of losses, if any; ii) appropriations to the reserve fund; iii) appropriations to the staff welfare fund; and iv) appropriations to an enterprise expansion fund if determined by the Board of Directors. Under current regulation, appropriations to the reserve fund should be at least 10% of the after tax net income determined in accordance with the PRC GAAP until the reserve is equal to 50% of PRC subsidiary's registered capital; appropriations to the staff welfare fund are at a percentage, as determined by the Board of Directors, of the after tax net income determined in accordance with the PRC GAAP; appropriations to the enterprise expansion fund are made at the discretion of the Board of Directors. The reserve fund and enterprise expansion fund are recorded as part of shareholders' equity but are not available for distribution to shareholders other than in liquidation; while the staff welfare fund is recorded as a liability and is not for distribution to shareholders. As at December 31, 2005, the Company's reserve fund is \$1.91 million, 7.70% of the Company's registered capital.

Liquidity and Capital Resources

As of December 31, 2005, Dragon had current liabilities of \$41.30million and current assets of \$27.99 million, including cash balance of \$1.31 million and accounts receivables of \$7.91 million. The working capital deficiency is mainly due to the additional bank loan and payables incurred to finance its working capital requirement for the Chemical Division and investment in the new EPO workshop and Freeze-dry Injectable workshop.

The Company has developed and is implementing a plan to decrease its debt and increase its working capital which will allow the Company to continue operations.

To meet these objectives, the Company plans to seek additional equity through the conversion of some of its liabilities and expects to raise funds through a private investment in order to support existing operations and expand

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

the range and scope of its business. The Company has also significantly increased production levels to generate additional cash flow under contracted supply agreements. In addition, the Company intends to continue to renegotiate and extend loans, as required, when they become due, as has been done in the past. There is no assurance that such additional funds will be available for the Company on acceptable terms, if at all. If adequate funds are not available or not available on acceptable terms, the Company may be required to scale back or abandon some activities. Management believes that actions presently taken provide the opportunity for the Company to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time.

26

As of December 31, 2005, Dragon had current liabilities of \$41,303,095 as follows:

Accounts Payable		\$6,476,539
Accrued Retirement Benefits - current portion		\$90,714
Other Payables and Accrued Expenses		\$17,866,466
Due to Related Companies		\$61,993
Notes payable		\$ 3,327,829
Loans Payable-Short Term:		
Loan payable to a bank, interest rate of 7.395% per annum, guaranteed by a third party, due April 2006	\$594,796	
Loan payable to a bank, interest rate of 6.039% per annum, secured by leasehold land and fixed assets of \$3,031,680, due April 2006	\$1,858,736	
Loan payable to a bank, interest rate of 6.136% per annum, secured by leasehold land and fixed assets of \$5,127,112, due May 2006	\$3,717,472	
Loan payable to a bank, interest rate of 7.254% per annum, secured by leasehold land and fixed assets of \$1,230,706, due September 2006	\$619,579	
Loan payable to a bank, interest rate of 7.254% per annum, secured by leasehold land and fixed assets of \$721,832, due September 2006	\$208,178	
Loan payable to a bank, interest rate of 5.76% per annum, secured by leasehold land and fixed assets of \$9,506,733, due November 2006	\$6,480,793	
Loans Payable - Short Term Subtotal		\$13,479,554
 Total Current Liabilities		 \$41,303,095

The Accounts payable were incurred as part of the normal course of business of Dragon while other payables and accrued expenses were incurred as part of the investment in establishing the Chemical Division and investment in the new EPO workshop and Freeze-dry Injectable workshop.

As of December 31, 2005, Dragon had outstanding short-term loans (less than one year term) totaling \$13.48 million. Dragon believes that it will be successful in the renegotiating loans due based on the assumption that the Company has enhanced its ability to generate additional cash flow from its operation since the loans were originally entered into. Since then, the Company's Chemical Division commenced production and began generating revenues and cash flow. Further, it entered into a three-year long term supply contract with a large Indian pharmaceutical company to provide its products from the Chemical Division.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Long-term Liabilities:

At December 31, 2005, Dragon had long-term liabilities of \$27,433,624 as follows:

Long-term accounts payable, discounted at 6.5%	\$12,216,832
Long-term retirement benefits	\$620,396
Loan Payable - Long Term	
Loan payable to a bank, interest rate of 6.039% per annum, secured by leasehold land and fixed assets of \$3,679,937, due April 2007	\$6,815,366
Loan payable to a company, noninterest bearing and unsecured, due June 30, 2007	\$4,709,643
Loan payable to a company, noninterest bearing and unsecured, due December 31, 2007	\$3,071,387
Loan Payable - Long Term	\$14,596,396
Total Long-term Liabilities	\$27,433,624

27

As of December 31, 2005, the Company had long-term retirement benefits of \$0.62 million, which was incurred in July 2003 when Shanxi Weiqida acquired land and buildings from a government liquidator in exchange for assuming certain future employment, healthcare and land acquisition costs of the factory and its former employees during July 2003. The Company is required to pay certain minimum wages and health care costs until the date of their employment, retirement or death, whichever occurs first. The total amount of the liabilities assumed on the closing date was \$8.90 million, which approximated the appraised value of the land. As of December 31, 2005, Shanxi Weiqida had employed 674 former employees, and 237 former employees have retired. Shanxi Weiqida has calculated the related asset value by computing the net present value of the future expected payments to the remaining 143 employees assuming an interest rate of 3%. As of December 31, 2005, 143 former employees of Datong Pharmaceutical remained as the obligation of Dragon.

Dragon had long-term loans payables (one to two years) totaling approximately \$14.60 million due April through December 2007, in addition to long-term accounts payable of \$14.27 million which will become due between June 2007 and December 2008. The long-term accounts payable, which are non-interest bearing, have been discounted at 6.5% and are carried in the financial statements at \$12.22 million.

During the year ended December 31, 2005, Dragon financed its operations, development of its new EPO and freeze-dry injectable facilities, and increased production level at its Chemical Division through operating revenues, accounts payables and short-term loans. The Company had anticipated that it would increase its production level through an equity financing. However, as discussed below, the anticipated financing has taken longer than expected. As a result, Dragon was not able to increase its production level as quickly as anticipated. However, during July 2005, Dragon was able to increase its production level of 7-ACA, one of the key products of the Chemical Division, from 30% (of the original capacity of 400 tons) to approximately 60% (of the newly improved capacity of 600 tons) and believes that its sales of the Chemical Division will increase. Dragon intends to seek additional funding through equity financing to improve its financial position, which may include conversion of certain receivables by certain vendors of Shanxi Weiqida into Dragon common stock.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Subsequent to December 31, 2005, the Company entered into a Loan agreement with a bank for \$2,478,315 bearing interest at a rate of 6.138% per annum, secured by fixed assets of \$10,787,902, and is due in January 2007.

ITEM 7. FINANCIAL STATEMENTS

The following Financial Statements pertaining to Dragon are filed as part of this annual report:

Report of Independent Registered Public Accounting Firms.....	29
Year-end Consolidated Balance Sheets.....	31
Year-end Consolidated Statements of Stockholders' Equity.....	32
Year-end Consolidated Statements of Operations.....	33
Year-end Consolidated Statements of Cash Flows.....	34
Notes to Consolidated Financial Statements.....	35

28

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of
Dragon Pharmaceutical Inc.

We have audited the consolidated balance sheet of Dragon Pharmaceutical Inc. as at December 31, 2005 and the consolidated statements of operations, stockholders' equity and cash flows for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion in these financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Oversight Board (United States). Those standards require that we plan and perform an audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial reporting. Our audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects the consolidated financial position of the Company as at December 31, 2005 and the consolidated results of its operations and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

As discussed in Note 1 to the financial statements, the Company's recurring working capital deficiency raise substantial doubt about its ability to continue as a going concern. Management's plan in regard to these matters is also described in Note 1 (A). These financial statements do not include any

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

adjustments that might result from the outcome of this uncertainty.

The restated consolidated financial statements as at December 31, 2004 and for the year then ended were audited by other auditors who expressed an opinion without reservation on those statements in their report dated March 14, 2005, except for Note 20, as to which the date is September 16, 2005.

Vancouver, Canada,
January 26, 2006,
(except for Note 21 which is of March 28, 2006)

/s/ Ernst & Young LLP
Chartered Accountants

29

LOGO
WEBB & COMPANY, P.A.
Certified Public Accountants

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors of:
Oriental Wave Holding Limited and Subsidiary

We have audited the accompanying consolidated balance sheet of Oriental Wave Holding Limited and subsidiary as of December 31, 2004, and the related statements of operations and comprehensive income, changes in stockholders' equity and cash flows for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly in all material respects, the financial position of Oriental Wave Holding Limited and subsidiary as of December 31, 2004 and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

As discussed in Note 20, the Company restated its consolidated financial statements for the year ended December 31, 2004.

/s/ Webb & Company, P.A.
WEBB & COMPANY, P.A.

Boynton Beach, Florida
March 14, 2005, except for Note 20, as to which the date is September 16, 2005

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

1501 Corporate Drive Suite 290 . Boynton Beach, FL 33426
 Telephone: (561) 752-1721 . Fax: (561) 734-8562
 www.cpawebb.com

30

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
 CONSOLIDATED BALANCE SHEETS
 AS AT DECEMBER 31, 2005 AND 2004
 Expressed in US Dollars
 (Basis of Presentation - Note 1)

	ASSETS -----	
	Notes	
	-----	-----
CURRENT ASSETS		
Cash and cash equivalents	19	\$
Restricted cash	11,19	
Accounts receivable, net of allowances	2	
Inventories, net	3	
Value added tax receivable		
Other receivables		
Prepaid expenses		
Total Current Assets		-----
PROPERTY AND EQUIPMENT, NET	5,10	-----
OTHER ASSETS		
Intangible assets, net	7	
Investments -cost		
Goodwill		
Total Other Assets		-----
TOTAL ASSETS		\$
-----		=====
LIABILITIES AND STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES		
Accounts payable		\$
Accrued retirement benefits	8	
Other payables and accrued liabilities	9	
Loans payable - short-term	10	
Notes payable	11	
Due to related companies	4	
Total Current Liabilities		-----
LONG-TERM LIABILITIES		
Long term accounts payable	12	
Long term retirement benefits	8	
Loans payable - long-term	10	
Due to related companies	4	

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Total Long-Term Liabilities	
TOTAL LIABILITIES	
COMMITMENTS AND CONTINGENCIES (Note 15)	
STOCKHOLDERS' EQUITY	
Authorized: 200,000,000 common shares at par value of \$0.001 each	
Issued and outstanding: 62,878,004 (December 31, 2004: 44,502,004)	
common shares	
Additional paid-in capital	
Retained earnings	
Reserves	
Accumulated other comprehensive income	
Due from stockholders	
Total Stockholders' Equity	
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$
-----	=====

The accompanying notes are an integral part of these consolidated financial statements.

31

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

	Note	2005	
	-----	-----	
NET SALES	13	\$ 56,244,794	\$
COST OF SALES		42,295,839	
GROSS PROFIT		13,948,955	
OPERATING EXPENSES			
Selling expense		4,839,138	
General and administrative expenses		6,672,665	
Depreciation and amortization		1,088,766	
Total Operating Expenses		12,600,569	
INCOME FROM OPERATIONS		1,348,386	
OTHER INCOME (EXPENSE)			
Interest expense		(1,332,046)	
Other income		109,393	
Funds Released by Chinese Government Liquidator	14	885,864	

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Other expense		(281,793)	

Total other income (expenses)		(618,582)	

INCOME BEFORE TAXES		729,804	
INCOME TAX EXPENSE	17	547,234	

NET INCOME		182,570	
OTHER COMPREHENSIVE INCOME			
Foreign currency translation		750,102	

COMPREHENSIVE INCOME		\$ 932,672	\$
		=====	=====
Earnings per share - basic and diluted		\$ 0.00	\$
		=====	=====
Weighted average number of shares outstanding during the year - basic		62,273,862	
		=====	=====
- diluted		62,610,110	
		=====	=====

The accompanying notes are an integral part of these consolidated financial statements.

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

	Common Stock		Additional	RESTATED	RESTATED
	Shares	Amount	Paid-In	(NOTE 20)	(NOTE 20)
	-----	-----	-----	Retained	Reserves
	-----	-----	-----	Earnings	-----
Balance, December 31, 2003, adjusted for the effect of recapitalization of reverse acquisition (Note 6(B))	44,502,004	\$44,502	\$7,841,363	\$6,054,864	\$1,286,784
Registered capital appropriation (Note 16(A))	-	-	6,141,639	(6,141,639)	-
Notes receivable - stockholders	-	-	-	-	-
Net income for the year ended December 31, 2004	-	-	-	6,362,423	-
Transfer from retained earnings for reserves	-	-	-	(6,275,648)	6,275,648
	-----	-----	-----	-----	-----
Balance, December 31, 2004	44,502,004	\$44,502	13,983,002	-	7,562,432
Reverse acquisition (6(B))	8,376,000	18,376	7,919,370	-	-

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Related party debt settled for equity (Note 18)	-	-	2,415,458	-	-
Notes receivable - stockholders	-	-	-	-	-
Comprehensive income (loss) - foreign currency translation	-	-	-	-	-
Transfer from appropriated earnings - to retained earnings				5,204,022	(5,204,022)
- to liabilities (Note 16(B))					(17,103)
Transfer from retained earnings for reserves (Note 16(B))				(286,701)	286,701
Net income for the year	-	-	-	182,570	-
Balance, December 31, 2005	62,878,004	\$ 62,878	\$24,317,830	\$5,099,891	\$2,628,008

The accompanying notes are an integral part of these consolidated financial statements.

33

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES:

Net income
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization
Provision for doubtful accounts
Provision for (recovery from) obsolete inventories
Loss on disposition of assets
Write-off of acquired research and development (Note 6(B))
Funds Released by Chinese Government Liquidator (Note 14)
Changes in operating assets and liabilities, net of effect of reverse acquisition (Note 6(B)), (increase) decrease in:
Accounts receivable
Inventories
Value added tax receivable
Prepaid expenses
Other receivables
Deposits
Increase (decrease) in:
Accounts payable
Other payables and accrued expenses

Net Cash Provided By (Used In) Operating Activities

CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES:

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Purchase of property and equipment
Purchase of investment
Cash and cash equivalents acquired in connection with reverse acquisition (Note 6(B))

Net Cash Provided By (Used In) Investing Activities

CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES:

Proceeds from loans payable
Due to related companies
Due from stockholder

Net Cash Provided By (Used In) Financing Activities

LOSS ON TRANSLATION OF FOREIGN CURRENCY

NET INCREASE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR

CASH AND CASH EQUIVALENTS AT END OF YEAR

Cash paid during the year for interest expense

Cash paid during the year for income taxes

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: During March 2005, \$2,415,458 of loans payable to an entity related to a director of the Company was converted into equity of the Company (Note 18).

The Company capitalized interest of \$242,066 and \$666,927 during 2005 and 2004, respectively.

The accompanying notes are an integral part of these consolidated financial statements.

34

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

(A) Organization and Basis of Presentation

Pursuant to a share purchase agreement, dated June 11, 2004, Dragon Pharmaceutical Inc. (the "Company") acquired 100% of the issued and outstanding shares of Oriental Wave Holding Limited ("Oriental Wave") by issuing 44,502,004 common shares of the Company. This transaction was completed on January 12, 2005 and has been accounted for as a reverse acquisition (See Note 6(B)). Accounting principles applicable to reverse acquisition has been applied to record the acquisition. Under this basis of accounting, Oriental Wave is the acquirer and, accordingly, the consolidated entity is considered to be a continuation of Oriental Wave with the net assets of the Company deemed to have been acquired and

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

recorded at its fair market value. The Statements of operations includes the results of Oriental Wave for the year ended December 31, 2005 and those of the Company from January 13 to December 31, 2005.

Oriental Wave was incorporated in the British Virgin Islands on January 7, 2003. Shanxi Weiqida Pharmaceutical Company Limited ("Shanxi Weiqida"), a People's Republic of China limited liability company was incorporated on January 22, 2002. Shanxi Weiqida is principally engaged in research and development, manufacturing, and selling of pharmaceutical products in the People's Republic of China ("PRC").

During 2003, Shanxi Weiqida's shareholders exchanged 100% of their ownership of Shanxi Weiqida for 50,000 shares of Oriental Wave under a reorganization plan. The transfer was accounted for as a reorganization of entities under common control as the companies were beneficially owned by identical shareholders and share common management. The financial statements have been prepared as if the reorganization had occurred retroactively.

The consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries: Oriental Wave, Shanxi Weiqida, Beijing Weixang Bio-tech Co. Ltd., Allwin Newtech Ltd., Sanhe Kailong Bio-pharmaceutical Co., Ltd., Nanjing Huaxin Bio-pharmaceutical Co. Ltd. ("Huaxin"), Allwin Biotrade Inc. and Dragon Pharmaceuticals (Canada) Inc. All significant intercompany balances and transactions have been eliminated upon consolidation.

The accompanying consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has a working capital deficiency, however, the Company has developed and is implementing a plan to decrease its debt and increase its working capital which will allow the Company to continue operations.

To meet these objectives, the Company plans to seek additional equity through the conversion of some of its liabilities and expects to raise funds through a private investment in order to support existing operations and expand the range and scope of its business. The Company has also significantly increased production levels to generate additional cash flow under contracted supply agreements. In addition, the Company intends to continue to renegotiate and extend loans, as required, when they become due, as has been done in the past. There is no assurance that such additional funds will be available for the Company on acceptable terms, if at all. If adequate funds are not available or not available on acceptable terms, the Company may be required to scale back or abandon some activities. Management believes that actions presently taken provide the opportunity for the Company to continue as a going concern. The Company's ability to achieve these objectives cannot be determined at this time.

35

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

These conditions raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might result from this uncertainty.

(B) Use of Estimates

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

In preparing consolidated financial statements in conformity with U.S. generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.

(C) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.

(D) Accounts Receivable

The Company extends unsecured credit to its customers in the ordinary course of business but mitigates the associated risks by performing credit checks and actively pursuing past due accounts. An allowance for doubtful accounts is established and recorded based on management's assessment of the credit history with the customer and current relationships with them.

(E) Investments

During the twelve months ended December 31, 2004, the Company made an investment in a private company of \$12,077. The investment represents less than 1% of the total equity outstanding of the private company outstanding as of December 31, 2005. The private company investment is carried at cost and written down to fair market value when indications exist that this investment has other than temporarily declined in value. As of December 31, 2005, no impairment in the value of the investment has been recorded.

(F) Inventories

Inventories are stated at the lower of cost or replacement cost with respect to raw materials and the lower of cost and net realizable value with respect to finished goods and work-in-progress, cost being determined on a weighted average basis. The Company provides inventory allowances based on excess and obsolete inventories determined principally by customer demand and product expiration dates.

(G) Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives are as follows:

36

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

Buildings	50 Years
Plant and machinery	10 Years
Motor vehicles	8 Years
Furniture, fixtures and	

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

equipment	5 Years
Leasehold improvements	Term of Lease (5 - 10 years)

Land use rights are stated at cost, less accumulated amortization. The land use rights are amortized over the term of the relevant rights of 50 years from the date of acquisition.

Depreciable assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable based on projected undiscounted cash flows associated with the assets. A loss is recognized for the difference between the fair value and the carrying amount of the assets. Fair value is determined based upon market quote, if available, or is based on valuation techniques.

(H) Fair Value of Financial Instruments

The carrying amount of the Company's cash and cash equivalents, receivables, investments, amounts due to and from related parties and loans and other payables approximates their fair value. The fair value of the loans payables are estimated using discounted cash flow analysis, based upon the Company's current borrowing rates, and approximate their carrying value.

(I) Intangible Assets

Intangible assets represent acquired customer bases and product technology, licenses and permits for the production and sales of pharmaceutical products in China and are amortized on a straight-line basis over a period of seven or ten years.

Intangible assets are tested for impairment whenever events or circumstances indicate that a carrying amount may not be recoverable. An impairment loss would be recognized when the carrying amount of an asset exceeds the estimated undiscounted cash flows used in determining the fair value of the assets. The amount of the impairment loss to be recorded is calculated by the excess of the assets carrying value over its fair value. Fair value is determined using a discounted cash flow analysis.

(J) Goodwill

Goodwill represents the excess of the cost of investments in subsidiaries over the fair value of the net identifiable assets acquired. The Company reviews the goodwill of all of its reporting units on at least an annual basis to ensure its fair value is in excess of its carrying value in the financial statements. Any impairment in the value of goodwill is charged to income in the period such impairment is determined.

(K) Revenue Recognition

The Company recognizes revenue, net of estimated provisions for returns, rebates and sales allowances from the sale of pharmaceutical products at the time when the product is delivered to the customer. Revenues are recognized only when the Company has transferred to the customer the significant risk and rewards of ownership of the goods, title to the products transfers, the amount is fixed and determinable, evidence of an

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Expressed in US Dollars

agreement exists, there is reasonable assurance of collection of the sales proceeds, the Company has no future obligations and the customer bears the risk of loss.

(L) Advertising Costs

Advertising costs are expensed as incurred. Advertising expense totaled \$71,755 and \$63,692 for the years ended December 31, 2005 and 2004, respectively.

(M) Research and Development

Research and development costs related to both present and future products are expensed as incurred. Total expenditures on research and development charged to general and administrative expenses for the years ended December 31, 2005 and 2004 were \$208,414 and \$193,188, respectively.

(N) Income Taxes

The Company accounts for income taxes under the Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("Statement 109"). Under Statement 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under Statement 109, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company located its factories in a special economic region in China. This economic region allows foreign enterprises a two-year income tax exemption from central government tax beginning in the first year after they become profitable, being the year commencing on January 1, 2003 to December 31, 2004 and a 50% income tax reduction for the following three years, being 2005 to 2007. Shanxi Weiqida was approved as a wholly owned foreign enterprise in October 2002.

(O) Foreign Currency Translation

Shanxi Weiqida, Huaxin and Dragon Pharmaceutical (Canada) Inc maintain their accounting records in their functional currencies (ie. Renminbi Yuan, Renminbi Yuan and Canadian dollar, respectively), however, the Company reports in U.S. dollars. Transactions denominated in currencies other than US dollars translated into United States dollars using period end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transaction occurred. Net gains and losses resulting from foreign exchange translations are included in the statements of operations and stockholder's equity as other comprehensive gain (loss). The revenues and expenses of the Company which are maintained in RMB are translated to U.S. dollars at US\$1.00 = RMB 8.20 during the year with the assets and liabilities of the Company maintained in RMB translated to U.S. dollars at US\$1.00 = RMB 8.07.

(P) Other Comprehensive Income

The Company has adopted SFAS No. 130, "Reporting Comprehensive Income", which establishes standards for reporting and display of comprehensive income, its components and accumulated balances. The Company is disclosing

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

this information on its Statement of Stockholders' Equity. Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners.

38

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

(Q) Segments

The Company operates in three reportable segments, Chemical Division, Pharma Division and Biotech Division.

(R) Earnings Per Share

Earnings per share are computed using the weighted average number of shares outstanding during the period. Diluted earnings per share, as determined using the treasury method, is equal to the basic income per share as common stock equivalents consisting of options to acquire 6,737,500 common shares that are outstanding at December 31, 2005 (2004: Nil) are not significantly dilutive, however, they may be dilutive in the future.

(S) Reclassifications

Certain 2004 balances have been reclassified to conform to the 2005 presentation.

(T) Stock Based Compensation

The Company adopted the disclosure-only provisions of Statement of Financial Accounting Standards No. 123 (SFAS 123), "Accounting for Stock-based Compensation", as amended by SFAS No. 148 "Accounting for Stock-based Compensation - Transition and Disclosure - An amendment of SFAS No. 123". SFAS 123 encourages, but does not require, companies to adopt a fair value based method for determining expense related to stock-based compensation. The Company continues to account for stock-based compensation issued to employees and directors using the intrinsic value method as prescribed under Accounting Principles Board Opinion (APB) No. 25, "Accounting for Stock Issued to Employees" and related Interpretations (Note 1(U)). The Company has a stock option plan which is disclosed in detail in Note 16(c).

(U) Recent Accounting Pronouncements

In November 2004, the FASB issued SFAS No. 151, "Inventory Costs--an amendment of ARB No. 43, Chapter 4", which is the result of the FASB's project to reduce differences between U.S. and international accounting standards. SFAS No. 151 requires idle facility costs, abnormal freight, handling costs, and amounts of wasted materials (spoilage) be treated as current-period costs. Under this concept, if the costs associated with the actual level of spoilage or production defects are greater than the costs associated with the range of normal spoilage or defects, the difference would be charged to current-period expense, not included in inventory costs. SFAS No. 151 will be effective for inventory costs incurred during fiscal years beginning after June 15, 2005. The adoption of SFAS No. 151 is not expected to have an impact on the Company's consolidated financial statements.

In December 2004, the FASB issued SFAS No. 123(R), "Accounting for

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Stock-Based Compensation". SFAS 123(R) establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. This Statement focuses primarily on accounting for transactions in which an entity obtains employee services in share-based payment transactions. SFAS 123(R) requires that the fair value of such equity instruments be recognized as expense in the historical financial statements as services are performed. Prior to SFAS 123(R), only certain pro-forma disclosures of fair value were required. SFAS 123(R) will be adopted by the Company effective as of the beginning of the first interim and annual reporting period that begins after December 15, 2005 and will result in the Company recording a non-cash stock based compensation based upon the fair value of the options at the time.

39

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
 Expressed in US Dollars

In May 2005, the FASB issued Statement of Financial Accounting Standards SFAS No. 154, "Accounting Changes and Error Corrections, a replacement of APB Opinion No. 20 and FASB Statement No. 3." SFAS 154 requires retrospective application to prior periods' financial statements for changes in accounting principle, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. SFAS 154 also requires that retrospective application of a change in accounting principle be limited to the direct effects of the change. Indirect effects of a change in accounting principle, such as a change in non-discretionary profit-sharing payments resulting from an accounting change, should be recognized in the period of the accounting change. SFAS 154 also requires that a change in depreciation, amortization, or depletion method for long-lived, non-financial assets be accounted for as a change in accounting estimate effected by a change in accounting principle. SFAS 154 is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005. Early adoption is permitted for accounting changes and corrections of errors made in fiscal years beginning after the date this Statement is issued. The adoption of this new accounting pronouncement is not expected to have a material impact on its consolidated financial position, results of operations or cash flows.

NOTE 2 ACCOUNTS RECEIVABLE

Accounts receivable at December 31, 2005 and December 31, 2004 consisted of the following:

		December 31, 2005

Trade and other receivables	\$	8,409,047
Less: allowance for doubtful accounts		502,327

Accounts receivable, net	\$	7,906,720
		=====

For the ended December 31, 2005, the Company recorded a provision for doubtful accounts of \$101,703 in the Consolidated Statements of Operations compared to \$124,574 for the year ended December 31, 2004.

NOTE 3 INVENTORIES

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Inventories at December 31, 2005 and December 31, 2004 consisted of the following:

	December 31, 2005
Raw materials	\$ 4,144,900
Work-in-progress	6,280,283
Finished goods	4,523,663

	14,948,846
Less: provision for obsolescence	817,111

	\$ 14,131,735
	=====

40

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

For the year ended December 31, 2005, the Company recorded a recovery from obsolete inventories of \$229,684, in the Consolidated Statements of Operations compared to a provision for obsolete inventories of \$613,378 for the year ended December 31, 2004.

NOTE 4 DUE TO RELATED PARTIES

The amounts due to related parties at December 31, 2005 and December 31, 2004 are unsecured and non-interest bearing:

	December 31, 2005

Due to a company owned by a stockholder and director due March 2006	\$ - \$
Due to the spouse of a shareholder and director	61,993
Due to a company owned by a stockholder and director due March 2006	-

	61,993
Less: current maturities	61,993

	\$ - \$
	=====

NOTE 5 PROPERTY AND EQUIPMENT

The following is a summary of property and equipment at December 31, 2005 and December 31, 2004:

December 31, 2005

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

	Cost	Accumulated Depreciation
	-----	-----
Plant and equipment	\$ 46,673,710	\$ 7,350,550
Land use rights and buildings	21,312,872	743,593
Motor vehicles	752,919	218,136
Furniture and office equipment	3,066,099	1,252,221
Leasehold improvements	1,020,949	1,018,504
Construction in progress	6,984,143	-
	-----	-----
	\$ 79,810,692	\$ 10,583,004
	=====	=====

41

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

	December 31, 2004	
	Cost	Accumulated Depreciation
	-----	-----
Plant and equipment	\$ 41,154,014	\$ 2,293,918
Land use rights and buildings	18,552,438	370,169
Motor vehicles	611,261	55,166
Furniture and office equipment	2,499,188	392,511
Construction in progress	2,691,179	-
	-----	-----
	\$ 65,508,080	\$ 3,111,764
	=====	=====

Depreciation expense for years ended the December 31, 2005 and 2004 was \$5,352,714 and \$2,612,981, respectively. Land use rights and equipment with a net book value of \$23.3 million are pledged as collateral for \$19.7 million in loans payable (Note 10).

NOTE 6 ACQUISITIONS

(A) Land Use Rights

During July 2003, the Company acquired Land Use Rights and buildings from a government liquidator in exchange for assuming certain future employment and healthcare costs of its former employees and Land Use Rights acquisition costs of the factory. The agreement requires the Company to pay certain minimum wages and health care costs until the date of their employment, retirement or death, whichever occurs first. The maximum amount of the liabilities assumed on the closing date was \$8,897,685 which approximates the appraised value of the Land Use Rights acquired. The

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Company has calculated the related asset value by computing the estimated fair value of the future expected payments to the remaining employees assuming an interest rate of 3% and has recorded the Land Use Rights at \$3,332,907 (See Notes 8 and 15(D)). Subsequent to the acquisition the Company rehired a number of the former employees, reducing the expected future payments required. The Company has accounted for the reduction of the obligation by reducing the amount of Land Use Rights recorded.

The cost of Land Use Rights as at December 31, 2005 and 2004 is as follows:

	December 31, 2005	RESTATED (NOTE 20) December 31, 2004
Original Cost recorded	\$ 3,332,907	\$ 3,332,907
Less: reduction of future accrued retirement benefit	1,389,799	1,389,799
Cost of Land Use Rights	\$ 1,943,108	\$ 1,943,108

42

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
 Expressed in US Dollars

The Land Use Rights, which are included in Property and equipment in the consolidated balance sheet, have been reduced by \$254,561 during the year ended December 31, 2005 (2004: \$1,135,238) and will be reduced in the future should payments be further reduced due to additional former employees being rehired.

(B) Oriental Wave Holding Limited

The Company completed the acquisition of Oriental Wave on January 12, 2005 whereby the Company issued 44,502,004 common shares in exchange for all of the issued and outstanding shares of Oriental Wave. The acquisition represented an important strategic step in strengthening the competitive position of the Company. The transaction has been approved by the Company's shareholders and the regulatory authorities, who also approved an increase in the authorized share capital to 200,000,000 common shares.

This transaction resulted in the former shareholders of Oriental Wave owning 68.35% of the issued and outstanding shares of the combined entity as of January 12, 2005. Accounting principles applicable to reverse acquisition has been applied to record the acquisition. Under this basis of accounting, Oriental Wave is the acquirer and, accordingly, the consolidated entity is considered to be a continuation of Oriental Wave with the net assets of the Company deemed to have been acquired and recorded at its fair market value of approximately \$7.9 million. The Statement of operations includes the results of Oriental Wave for the year ended December 31, 2005 and those of the Company from January 13 to December 31, 2005.

The allocation of the net assets acquired is as follows:

Cash and cash equivalents	\$ 2,103,481	
Accounts receivable	1,527,554	

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Inventories	549,189	
Prepaid and deposits	100,421	

Total Current Assets	4,280,645	
Property and equipment	785,742	
Intangible assets	3,380,222	
In-process research and development	265,000	
Goodwill	965,000	

Total Assets	9,676,609	
Less accounts payables and accrued liabilities	(1,738,863)	

Net assets acquired	\$ 7,937,746	=====

The intangible assets consist of the production technology and license and customer base acquired and are being amortized over a period of seven years. The in-process research and development costs of \$265,000 were written-off to other expense subsequent to the acquisition.

43

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
 Expressed in US Dollars

A summarized statement of operations for the Company for the twelve days ended January 12, 2005 is as follows:

Sales	\$ 145,435	
Gross Profit	109,059	
Total operating expenses	166,881	
Loss for the period	\$ (57,822)	

Pro-forma financial information for the year ended December 31, 2004, assuming the acquisition occurred January 1, 2004, are as follows:

	2004	

Sales	\$32,728,391	
Gross profit	15,042,058	
Net income	5,419,705	
Earnings per share	\$ 0.08	

NOTE 7 INTANGIBLE ASSETS

The Company acquired \$603,865 in licenses from a company related to a director in 2002 with the balance being recorded pursuant to the reverse acquisition of Oriental Wave (Note 6(B)).

Intangible assets consist of the following as of December 31, 2005 and December 31, 2004:

	December 31, 2005	December 31, 2004
	-----	-----
Production technology	\$ 1,670,223	\$ -
Product licenses	1,217,905	603,865

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Customer base	1,160,000	-
	-----	-----
	4,048,128	603,865
Less: accumulated amortization	681,062	171,096
	-----	-----
	\$ 3,367,066	\$ 432,769
	=====	=====

Amortization expense for years ended December 31, 2005 and 2004 was \$528,935 and \$60,386, respectively.

44

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
 Expressed in US Dollars

NOTE 8 ACCRUED RETIREMENT BENEFITS

During July 2003, the Company acquired Land Use Rights and buildings from a government liquidator. The present value of the accrued retirement benefits assumed is recorded at December 31, 2005 and December 31, 2004 as follows:

	December 31, 2005

Total liabilities assumed at closing date	\$ 8,897,685
Less: reduction of liability due to re-employment	(4,949,474)
Less: net present value of liabilities initially not expected to be paid	(615,304)

Present value of expected liabilities at closing date	3,332,907
Less: amounts paid and adjustment for liabilities not expected to be paid	2,621,797

	711,110
Less: current portion	90,714

	\$ 620,396 \$
	=====

Under the terms of the contract with the liquidator, the Company will remain contingently liable for these liabilities until the date of retirement or re-employment for each employee (See Notes 6(A) and 15).

NOTE 9 OTHER PAYABLES AND ACCRUED LIABILITIES

Other payables and accrued liabilities at December 31, 2005 and December 31, 2004 consist of the following:

December 31, 2005

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Machinery and equipment payable	\$	4,253,448	\$
Non-interest bearing demand loans		1,416,357	
Current portion of long term payables		7,157,013	
Accrued expenses		1,147,101	
Value added tax payables		277,052	
Income taxes payable		144,499	
Other taxes payable		159,809	
Deposits received from customers		3,311,187	
	\$	17,866,466	\$

45

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
 Expressed in US Dollars

NOTE 10 LOANS PAYABLE

The Loans payable, denominated in Renminbi Yuan, are as follows:

	December 31, 2005

RMB 6.68 million Loan payable to a bank, interest rate of 6.372% per annum, guaranteed by a third party, due June 2005	\$ -
RMB 30 million Loan payable to a bank, interest rate of 6.138% per annum, secured by property and equipment of \$5,127,329, due November 2005	
RMB 70 million Loan payable to a bank, interest rate of 6.039% per annum, secured by property and equipment, due April 2005	-
RMB 4.8 million Loan payable to a bank, interest rate of 8.874% per annum, guaranteed by an unrelated third party, due April 2006	594,796
RMB 15,000,000 Loan payable to a bank, interest rate of 6.138% per annum, secured by property and equipment of \$3,031,680, due April 2006	1,858,736
RMB 30 million Loan payable to a bank, interest rate of 6.138% per annum, secured by property and equipment of \$5,127,112, due May 2006	3,717,472
RMB 5 million Loan payable to a bank, interest rate of 7.254% per annum, secured by property and equipment of \$1,230,706, due September 2006	619,579
RMB 1.6 million Loan payable to a bank, interest rate of 7.254% per annum, secured by property and equipment of \$721,832, due September 2006	208,178

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

RMB 52.3 million Loan payable to a bank, interest rate of 6.92% per annum, secured by property and equipment of \$9,506,733, due November 2006	6,480,793
RMB 55 million Loan payable to a bank, interest rate of 6.336% per annum, secured by property and equipment of \$3,679,937, due April 2007	6,815,366
RMB 38 million Loan payable to a company, non-interest bearing and unsecured, due June 30, 2007	4,709,643

46

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

	December 31, 2005	

RMB 24.79 million Loan payable to a company, non-interest bearing and unsecured, due December 2007	3,071,387	

	28,075,950	
Less current maturities	13,479,554	

	\$ 14,596,396	\$
	=====	

Maturities are as follows:

Fiscal year ended December 31,		
2006		\$
2007		\$

NOTE 11 NOTES PAYABLE

The Company has issued a number of notes payable to vendors totaling \$3,327,829. These notes are due between February 2006 and June 2006, are non-interest bearing and are secured by \$3,327,829 in bank deposits. The bank deposits may be used only for the purpose of repaying the notes.

NOTE 12 LONG TERM ACCOUNTS PAYABLE

	December 31, 2005	December 31, 2004
	-----	-----
Non interest bearing amounts payable to contractors related to the acquisition of plant and equipment. The amounts have been discounted using a rate of 6.5% as a result of term		

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

modifications made in 2005. The discount has been applied against the cost of the plant and equipment acquired.

\$ 12,216,832	\$ 17,250,874
=====	=====

During the year the Company accreted interest of \$146,949 (2004: \$Nil).

Future annual payments are as follows:

2007	\$	1,855,261
2008		12,409,757

	\$	14,265,018
		=====

47

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
 Expressed in US Dollars

NOTE 13 SEGMENTS

The Company operates in three reportable segments, the Pharma Division, Chemical Division and Biotech Division. The Pharma Division produces chemical generic, mainly anti-infectious, drugs. The Chemical Division produces the bulk intermediate or ingredient to sell to other pharmaceutical companies for further processing and formulation into finished products. The Biotech Division produces Erythropoietin or EPO, an injection that stimulates red blood cell. The accounting policies of the segments are the same as described in the summary of significant accounting policies. The Company evaluates segment performance based on gross profit. All sales by division were to external customers (see Note 19 also). As a result, the components of gross profit for one segment may not be comparable to another segment. The following is a summary of the Company's segment information for the years ended December 31, 2005 and 2004 and as of December 31, 2005 and December 31, 2004.

	Chemical Division	Pharma Division	Biotech Division
	-----	-----	-----
2005			
Sales	\$ 27,326,459	\$ 25,084,011	\$ 3,834
Gross profit	1,084,543	10,081,972	2,782
Depreciation and amortization	4,307,874	689,986	883
As at December 31, 2005			
Total assets	75,831,748	17,601,551	8,133
Additions to long-lived assets	10,238,939	116,961	1,800
Intangible assets	47,336	382,072	2,937
2004			
Year ended December 31, 2004			
Sales	\$ 4,248,906	\$ 24,774,224	\$
Gross profit	216,380	12,666,445	

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Depreciation and amortization RESTATED (NOTE 20)	2,033,933	639,434
As at December 31, 2004		
Total assets		
RESTATED (NOTE 20)	66,726,390	23,611,914
Additions to long-lived assets	27,295,156	852,773
Intangible assets	-	432,769

48

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

NOTE 14 OTHER INCOME - Funds Released by Chinese Government Liquidator

In July 2003, the Company, through Shanxi Weiqida, acquired out of bankruptcy the Land Use Rights of a state-owned enterprise. (Please also refer to Note 6(A)) After entering into this transaction, the Company was approached by an unrelated state agency to administer certain benefits payable to former employees of the agency (the government liquidator) as the Company had already established an infrastructure to make payments to these employees for settlement of liabilities related to the transaction. As a result, during 2004, the Company received \$1,751,208 from the government liquidator, for the settlement of human resources related expenses of the bankrupt enterprise. As well, during the first quarter of 2005, a separate municipal agency, the Datong Municipal Government, approved the transfer of a fund with a balance of \$140,036 originally reserved for the employee housing welfare as part of the liquidation process of the state-owned enterprise. The two agencies, unrelated to the acquisition, allowed the Company to retain the cash balance of \$745,828 as well as the reserve of \$140,036 as payment for services provided by the Company. As a result, the Company recorded other income of \$885,864 during the current year to reflect the above transactions.

NOTE 15 COMMITMENTS AND CONTINGENCIES

(A) Employee Benefits

The full time employees of Shanxi Weiqida are entitled to employee benefits including medical care, worker compensation, unemployment insurance and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to accrue for those benefits based on certain percentages of the employees' salaries. The total provision for such employee benefits was \$442,536 and \$642,856 for the years ended December 31, 2005 and 2004, respectively. The Company is required to make contributions to the plans out of the amounts accrued for medical and pension benefits. The Chinese government is responsible for the medical benefits and the pension liability to be paid to these employees.

(B) Loan Guarantee

The Company has guaranteed a bank loan to a supplier in the amount of \$2,478,000 (RMB20 million) due on July 16, 2006. Interest on the loan is charged at 7.905% and the bank has the right to seek settlement from the Company for payment should the supplier fail to repay the loan. There is no recourse or possible recovery for the Company should the suppliers default on their bank loans. The maximum potential amount of future payments

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

(undiscounted) that the Company could be required to make is \$2,584,000 (RMB20.85 million). The Company provided the guarantees to these suppliers to maintain a good business relationship.

The Company has also issued a guarantee to a bank as security for loans to a third party vendor of \$2,478,000 (RMB20 million) due on September 26, 2007 and \$3,718,000 (RMB30 million) due on October 27, 2007. Interest is charged at the bank's base rate plus 5.9475 %. The bank has the right to seek settlement from the Company for payment should the third party vendor fail to repay the loan. The maximum potential amount of future payments (undiscounted) that the Company could be required to make is \$6,855,000 (RMB55.32 million). This vendor has pledged assets totaling \$8,699,000 (RMB70.2 million) to the Company for this guarantee.

49

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

(C) Capital Commitments

According to the Articles of Association of Shanxi Weiqida, the Company has to fulfil registered capital of \$19,704,877 (RMB 159,018,360) within five years from December 16, 2003. As of December 31, 2005, the Company has fulfilled \$15,037,562 (RMB 121,353,123) of registered capital requirement and has registered capital commitments of \$4,667,316 (See Note 16(A)).

(D) Contingent Employment Benefits

During July 2003, the Company acquired land and buildings from a government liquidator in exchange for assuming certain future employment, healthcare and land acquisition costs of the factory and its former employees. Under the terms of the contract with the liquidator, the Company will remain contingently liable for these liabilities until the earliest of date of retirement, re-employment or death for each employee. As of December 31, 2005, the Company has rehired 674 former employees, 237 employees have retired and 143 former employees remain unemployed. If the Company is unable to provide continued employment to these remaining unemployed individuals, it will be liable to pay them each approximately \$55 per month until his or her date of retirement, at age 60 or 50, respectively, or death, whichever comes first (See Notes 6 & 8).

(E) Operating Leases

The Company has entered into an operating lease agreement for their administrative offices in Vancouver for an amount escalating from CDN\$200,000 to CDN\$232,000 (US\$170,000 to US\$198,000) per annum until March 31, 2007. Minimum payments required under the agreement are as follows:

2006	\$ 198,322
2007	49,949
Total	\$ 248,271

Subsequent to December 31, 2005, the Company subleased the premises and entered into a new lease agreement (see Note 21(a)).

The Company closed Huaxin's production in Nanjing, effective July 31, 2005, and has completed construction of a new facility in Datong, China at the

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

site of the manufacturing facilities of Oriental Wave. The Company negotiated the termination of its lease, without penalty, though the Company agreed to relinquish some fixtures and equipment with a carrying value of RMB 2.23 million (\$271,500) to the landlord in exchange for the forgiveness of RMB785,000 (\$96,000) in past rent payable. In addition, the Company paid approximately RMB 600,000 (\$70,000) relating to severance and benefit costs associated with the closure.

(F) Cell Line Development

The Company has contracted with a European Institute of Biotechnology to develop a high yield proprietary cell line and production process technology for the Company. Product from this advanced technology will be used by the Company to enter the European market, once certain competitor's patents expire. The total cost of development is \$592,000 (EUROS 500,000) of which \$355,000 (EUROS 300,000) is yet to be incurred as of December 31, 2005.

Subsequent to December 31, 2005, the Company disposed of the cell line and related obligations. (see Note 21(b)).

50

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

NOTE 16 STOCKHOLDERS' EQUITY

(A) Capital Contribution (See note 15(C))

On January 31, 2005 and on February 22, 2005 Oriental Wave paid Shanxi Weiqida \$479,988 and \$198,682, respectively, towards its registered capital requirement under Chinese law. During 2004, Shanxi Weiqida appropriated \$6,141,639 in retained earnings and applied it toward the registered capital requirement.

(B) Reserves

Pursuant to PRC regulations, Shanxi Weiqida is required to make appropriations to reserves funds, comprising the reserve fund, staff welfare fund and enterprise expansion fund, based on after-tax net income determined in accordance with generally accepted accounting principles of the People's Republic of China (the "PRC GAAP"). Appropriation to the reserve fund should be at least 10% of the after tax net income determined in accordance with the PRC GAAP until the reserve is equal to 50% of Shanxi Weiqida's registered capital. The reserve fund is established for covering the potential loss. Appropriations to the staff welfare fund are at a percentage, as determined by the Board of Directors, of the after tax net income determined in accordance with the PRC GAAP. The staff welfare fund is established for the purpose of providing employee facilities and other collective benefits to the employees. Appropriations to the enterprise expansion fund are made at the discretion of the Board of Directors. The enterprise expansion fund is established for expanding business operation. The reserve fund and enterprise expansion fund are recorded as part of shareholders' equity but are not available for distribution to shareholders other than in liquidation; while the staff welfare fund is recorded as a liability and is not for distribution to shareholders. The appropriations for reserves are made by the Board of Directors on an annual basis. During the year the Company transferred \$5,204,022 in excess appropriations made in prior years from reserves to retained earnings. The Company also

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

appropriated reserves of \$286,701 based upon the current year's after tax net income.

(C) Stock Options

The Company has adopted the 2005 Stock Option Plan, effective August 13, 2005, which allows for the granting of options to Directors and Employees for a period of up to ten years. The Company did not grant any options during the year ended December 31, 2004. During the year ended December 31, 2005, the Company granted options to its directors and employees to purchase 5,920,000 shares at a weighted average price of \$0.91 per share, with 2,260,000 shares at exercise price of \$1.18 (being the market price at the time) expiring on January 12, 2010 and 3,660,000 shares at exercise price of \$0.74 (being the market price at the time) expiring on September 30, 2010. Options to purchase 4,320,000 shares were exercisable immediately with 400,000 options becoming available on January 12, 2006, 400,000 options becoming available on September 30, 2006, 400,000 options becoming available on January 12, 2007 and the balance of 400,000 options vesting on September 30, 2007.

51

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

The following summarizes stock option information for the year ended December 31, 2005:

	Shares
Options outstanding at December 31, 2003	2,599,000
Forfeited	(705,000)
Exercised	(145,000)
Options outstanding at December 31, 2004	1,749,000
Granted	5,920,000
Forfeited	(1,231,500)
Options outstanding at December 31, 2005	6,437,500
Options outstanding at December 31, 2005	6,437,500

See Note 21(d) also.

	Options Outstanding	
Range of	Weighted Average Remaining	Weighted Average

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Exercise Prices	Number Outstanding	Contractual Life	Exercise Price	Num Exerci
\$0.01 - \$1.00	4,010,000	4.53	\$0.73	
\$1.01 - \$2.00	2,427,500	3.85	\$1.22	
	-----	----	-----	
	6,437,500	4.27	\$0.92	
	=====	=====	=====	

The Company accounts for its stock-based compensation plan in accordance with APB Opinion No. 25, under which no compensation is recognized in connection with options granted to employees and directors except if options are granted with a strike price below fair value of the underlying stock. The Company adopted the disclosure requirements SFAS No. 123, Accounting for Stock-Based Compensation. Accordingly, the Company is required to calculate and present the pro forma effect of all awards granted. For disclosure purposes, the fair value of each option granted to an employee has been estimated as of the date of grant using the Black-Scholes option pricing model with the following assumptions: risk-free interest rate of 5.5%, dividend yield 0%, volatility of 90%, and expected lives of approximately 0 to 5 years. The weighted average fair value of the options granted during the period was \$0.69 for the options granted in January 2005 and \$0.43 for the options granted in September 2005. Based on the computed option values and the number of the options issued, had the Company recognized compensation expense, the following would have been its effect on the Company's net income and earnings per share:

52

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
 Expressed in US Dollars

	2005	RESTATED (NOTE 20) 2004
For the year ended December 31,		
Net income for the period:		
- as reported	\$ 182,570	\$6,362
- pro-forma	(\$2,419,044)	\$6,362
Basic and diluted income per share:		
- as reported	\$0.00	\$
- pro-forma	(\$0.04)	\$

NOTE 17 INCOME TAXES

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

- (a) Shanxi Weijida and Huaxin are subject to income taxes in China on their taxable income as reported in their statutory accounts at a tax rate in accordance with the relevant income tax laws.

Oriental Wave, Allwin Newtech Ltd. and Allwin Biotrade Inc are BVI companies and are not subject to income taxes. Dragon Pharmaceutical Inc. and Dragon Pharmaceutical (Canada) Inc. are U.S. and Canadian companies, respectively, and are subject to taxes in those jurisdictions.

The Company has structured its business and operations on an international basis. The Company's history is that they have also been involved in a number of business combinations. As a result the Company could be involved in various investigations, claims and tax reviews that arise in the ordinary course of business activities. Each of these matters is subject to various uncertainties and it is possible that some of these matters may be resolved unfavourably to the Company. The Company has established an accrual for matters that are probable and can be reasonably estimated. Management believes that any liability that may ultimately result from the resolution of these matters in excess of amounts provided will not have a material adverse effect on the financial position or results of operations of the Company.

- (b) The tax effect of temporary differences that give rise to significant components of the deferred tax assets (liability) are as follows:

	December 31, 2005	December 31, 2004
	-----	-----
Excess (deficiency) of tax cost over net book value of:		
Inventory	\$ 477,054	\$ 186,664
Property and equipment	2,353,111	1,692,170
Other net assets (liabilities)	(612,414)	415,806
Losses carried forward	3,706,881	-
	-----	-----
Total deferred tax assets	5,924,632	2,294,640
Less: valuation allowance	(5,924,632)	(2,294,640)
	-----	-----
Net deferred tax assets	\$ -	\$ -
	=====	=====

53

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

The valuation allowance is reviewed periodically. When circumstance change and this causes a change in management's judgment about the realizeability of deferred tax assets, the impact of the change on the valuation allowance is generally reflected in current income,

The company has non-capital losses carried forward of US \$7.9 million in Canada expiring between 2008 and 2015 and US \$3.0 million in the US expiring in 2021. As a result of the acquisition of Oriental Wave, a change in ownership under IRC Section 382 has occurred. As a result of the change in ownership, the U.S. pre-acquisition losses of the Company would be limited in their use to offset post-acquisition income earned by the U.S. entity. The Company has not determined the

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

limitation amount. The amount of losses being carried forward that are subject to this limitation is approximately \$3 million.

All income and taxes are attributable to foreign and continuing operations. A reconciliation of the federal statutory income tax, at the statutory rate of 35% to the Company's effective income tax rate, for the years ended December 31, 2005 and 2004 are as follows:

	2005	2004
Income before taxes	\$ 729,804	\$6,200,000
Statutory tax rate	35 %	
Income tax expense at statutory tax rates	255,431	2,000,000
Foreign tax rate differential	(498,905)	(2,000,000)
Expenses not deductible for income tax purposes	49,373	
Tax exempted income	(147,314)	
Non-recognition of benefit of loss carry forward	888,649	
Income tax expense	\$ 547,234	\$ 0

NOTE 18 RELATED PARTY TRANSACTIONS

During March 2005, \$2,415,458 of loans payable to an entity related to a director of the Company was converted into equity of the Company.

See Notes 4, 7 and 21(b) also.

NOTE 19 CONCENTRATIONS AND RISKS

81% and 95% of the Company's revenues for the years ended December 31, 2005 and 2004, respectively, were derived from customers located in China. The Company had sales of \$6,593,391 and \$644,100 in the Chemical and Biotech Divisions to customers in India, representing 13% of the Company's revenues for the year ended December 31, 2005. 99% and 100%, respectively of its assets at December 31, 2005 and 2004 were located in China.

Sales to the Company's five largest customers accounted for approximately 32.9% and 12.4% of the Company's sales for the years ended December 31, 2005 and 2004, respectively; while sales to the Company's largest customer accounted for approximately 11.9% and 2.7%, respectively. Amounts owing from one customer represented 11.8% of the Company's trade and other receivables at December 31, 2005.

The Company is exposed to the risk arising from changing interest rates. A detailed analysis of the Company's Loans Payable, together with their respective interest rates and maturity dates, are included in Note 10.

The majority of the Company's assets, liabilities, revenues and expenses are denominated in Renminbi, which was tied to the US Dollar and is now tied to a basket of currencies of China's largest trading partners, is not a freely convertible currency. The appreciation of the Renminbi against the US Dollar would result in an increase in the assets, liabilities, revenues and expenses of the Company and a foreign currency gain included in comprehensive income. Conversely, the devaluation of the Renminbi against the US Dollar would result in a decrease in the assets, liabilities,

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

revenues and expenses of the Company and a foreign currency loss included in comprehensive income. At December 31, 2005, approximately US\$774,369 of the cash and cash equivalents (December 31, 2004: US\$885,681) and all of the restricted cash are held in Renminbi.

54

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
 Expressed in US Dollars

NOTE 20 RESTATEMENT

As a result of a review of its accounting policies and applicable accounting pronouncements, the Company has concluded that the reduction of a future retirement benefit obligation related to the acquisition of a Land Use Right from a former state-owned enterprise in China by Oriental Wave Holding Limited ("Oriental Wave") in July 2003, should have been accounted for as a reduction to the recorded cost of the Land Use Right instead of as a non-operating gain from extinguishment of debt, as previously disclosed in Oriental Wave's 2004 financial statements. As a result, Oriental Wave's 2004 financial statements have been restated retroactive to June 2004 to reflect such change in accounting treatment.

The reduction of the future retirement benefit obligation during 2004, totaling \$1,135,238 million, which was recognized as a non-operating gain, has been recorded as a reduction to the cost of the Land Use Right. On a going forward basis, any similar reduction of the retirement benefit obligation will be treated as a reduction to the recorded cost of the Land Use Right. The effect on the financial statements is as follows:

	As at December 31, 2004	
	Restated	Previously Reported
Current assets	\$25,283,300	\$25,283,300
Property and equipment	62,396,316	63,520,202
Other assets	2,658,688	2,658,688
Total assets	\$ 90,338,304	\$ 91,462,190
Liabilities	\$ 68,800,517	\$ 68,800,517
Share capital	14,027,504	14,027,504
Retained earnings	7,562,432	8,686,318
Due from shareholder	(52,149)	(52,149)
Total equity	21,537,787	22,661,673
Total liabilities and equity	\$ 90,338,304	\$ 91,462,190

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

	Year ended December 31, 2004	
	Restated	Previously Reported
Net Sales	\$ 29,023,130	\$ 29,023,130
Cost of sales	16,140,305	16,140,305
Gross profit	12,882,825	12,882,825
Operating expenses	5,856,596	5,867,948
Income from operations	7,026,229	7,014,877
Other income (expense)	(211,983)	923,255
Income before taxes	6,814,246	7,938,132
Income tax expense	451,823	451,823
Net income	\$ 6,362,423	\$ 7,486,309
Net Income per share	\$ 0.14	\$ 0.17

55

DRAGON PHARMACEUTICAL INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004
Expressed in US Dollars

NOTE 21 SUBSEQUENT EVENTS

- (a) Subsequent to December 31, 2005, the Company subleased its current office space and entered into a new operating lease agreement in Vancouver for approximately CDN\$73,000 (US\$60,000) per annum until March 31, 2011. Revised total minimum payments required under the new and old (Note 15(e)) leases are as follows:

2006	\$ 260,675
2007	\$ 111,203
2008	\$ 61,750
2009	\$ 61,750
2010	\$ 61,750
Thereafter	\$ 15,437
	\$ 572,565

The Company anticipates recovering \$124,000 and \$41,000 during fiscal 2006 and 2007, respectively, under its sublease agreement.

- (b) Subsequent to December 31, 2005, the Company disposed of the cell line, and all applicable obligations relating, thereto, being developed for the Company to enter the European market. The cell line was sold to a Company controlled by a Director of the Company who was also the President of the Company prior to the transaction. The cell line had a carrying value of \$0 and was sold for \$1 million.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

- (c) Subsequent to December 31, 2005, the Company entered into a Loan agreement with a bank for \$2,478,315 bearing interest at a rate of 6.138% per annum, secured by property and equipment of \$10,787,902, and is due in January 2007.
- (d) Subsequent to December 31, 2005, the Company cancelled options to acquire 500,000 shares at an exercise price of \$0.74 that were granted on September 30, 2005.

56

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS AND ACCOUNTING AND FINANCIAL DISCLOSURE.

The Company was informed that Moore Stephens Ellis Foster Ltd. Chartered Accountants ("Moore Stephens"), who had served as our independent accountants for the year ended December 31, 2004, had merged with and into Ernst & Young LLP on May 5, 2005. On July 10, 2005, the Company's board of directors formally approved the engagement of Ernst & Young as the Company's independent registered public accounting firm for 2005. On July 12, 2005, the former Moore Stephens representative who is now associated with Ernst & Young informed the Company that the merger of Moore Stephens into Ernst & Young on May 5, 2005, effectively constituted their resignation as the Company's independent accountant responsible for auditing its financial statements, and that effective as of such date, Moore Stephens no longer acted as the Company's independent registered public accountant. Therefore, Ernst & Young LLP was engaged as the independent registered public accounting firm of the Registrant.

Moore Stephens' report on the Company's financial statements for the year ended December 31, 2004 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope, or accounting principles.

During the period covered by the report of Moore Stephens and up to the effective date of resignation, the Company had no disagreements with Moore Stephens, whether or not resolved, on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Moore Stephens, would have caused Moore Stephens to make reference to the subject matter of the disagreement in connection with its reports.

During the Company's previous two fiscal years and up to the effective date of resignation, the Company did not consult with Ernst & Young regarding any of the items described under Item 304(a)(1)(iv)(B), Item 304(a)(2) or Item 304(b) of Regulation S-B.

As the acquisition of Oriental Wave Holdings Ltd was deemed to be a reverse-take-over transaction, Oriental Wave is considered to be the parent company for accounting purposes. The independent accountant for Oriental Wave for the year ended December 31, 2004 was Webb & Company P.A.

ITEM 8A. CONTROLS AND PROCEDURES.

We carried out an evaluation, under the supervision and with the participation of the our management, including our Chief Executive Officer and Chief Financial Officer, about the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(e). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Form 10-KSB are effective in ensuring that information required to be disclosed

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission's rules and forms.

There were no changes to internal controls over financial reporting during the fiscal year.

57

ITEM 8B. OTHER INFORMATION

On January 6, 2006, Dragon Pharmaceutical, Inc. (the "Company") entered into an Assignment and Assumption agreement that, effective February 2, 2006, sold all of the Company's right, title and interest in its Development and Manufacturing Agreement dated October 31, 2003 between the Company and Polymun Scientific Immunobiological Forschung EmGH ("Polymun") to AS Biotech AG, a company controlled by Dr. Alexander Wick, a director of the Company, for \$1 million and assumption of all liabilities under the Development and Manufacturing Agreement.

Under the terms of the Development and Manufacturing Agreement, Polymun would develop a new EPO cell-line for the European market pursuant to which the Company would be granted a non-exclusive license to make, use, sell, offer to sell, input and/or export EPO in a specific market area. Under the terms of the Development and Manufacturing Agreement, the Company was responsible to make certain milestone payments to Polymun and was required to purchase certain quantities of EPO produced by Polymun. At the time the Assignment and Assumption Agreement was entered into, Polymun had produced no EPO.

In light of the time, effort and costs to develop a new line of EPO in Europe, the Company decided to sell the contract. No penalty was incurred with the sale.

The sale was approved by all directors of the Company present at the meeting with Dr. Wick abstaining.

Effective February 2, 2006, Dr. Wick resigned as president to the Company. He still remains as a director to the Company.

PART III

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.

As of December 31, 2005, we had eight directors consisting of Mr. Han, Mr. Weng, Ms. Liu, Dr. Wick, Dr. Sun, Mr. Mak, Mr. Frey and Mr. Li. At the annual meeting of shareholders held on August 1, 2005, Mr. Han, Mr. Weng, Ms. Liu, Dr. Wick and Dr. Sun were re-elected as directors. The Board subsequently appointed Mr. Mak, Mr. Frey and Mr. Li as directors. The following describes the background for Mr. Han, Mr. Weng, Ms. Liu, Dr. Wick, Dr. Sun, Mr. Mak, Mr. Frey and Mr. Li.

Description of Current Directors

Mr. Yanlin Han, age 42, is the Chief Executive Officer and the Chairman of the Board of Director of Dragon, positions he assumed in January 2005. He has been the Chairman of Oriental Wave and responsible for the overall strategic planning and direction of Oriental Wave starting the date he founded the company. Mr. Han has over 20 years of experience in the pharmaceutical industry in many positions like material buyer, product sales and manager for state-own

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

companies in China and has very extensive sales and production management experience in China. He founded his private company named Shanxi Tongling Pharmaceutical Company in 1994, which became the vehicle to acquire state-own pharmaceutical companies through bankruptcy process or contractual management agreements. Mr. Han set up a joint venture with a large Indian pharmaceutical company to produce pharmaceutical intermediates with mass fermentation technology. Mr. Han also serves as the Vice-President of Shanxi Province Foreign

58

Investment Enterprise Association and Vice-President of Datong City Trade Council. Mr. Han graduated from Shanxi Institute of Economic Management in 1986.

Mr. Zhanguo Weng, age 51, had been a Director of the Company since January 2005. Mr. Weng is the Vice President, China Operation, a Director of Dragon and the Chairman of Oriental Wave, responsible for the overall daily operations of Shanxi Weiqida. Mr. Weng has over 25 years of experience in pharmaceutical industry including being the General Manager for Shanxi Tongzhen Pharmaceutical Co. Ltd. from August 1997 to January 2002 and Superintendent for Datong No. 2 Pharmaceutical Factory from June 1992 to August 1997. He graduated from the Business Administration faculty of Shanxi Broadcasting University in 1986 and has also participated the Senior Program of MBA (Pharmaceutical Line) of People's University of China for two years.

Ms. Xuemei Liu, age 36, has been a Director of the Company since January 2005. Ms. Liu is currently the Chairman of Tera Science & Technology Development Co. Ltd. which engages in a wide range of investment projects in real estate development, coal trading and media and publishing industry. Prior to her present position as Chairman of Tera Science & Technology Development Co. Ltd., Ms. Liu was the vice general manager of Beijing Chemical Baifeng Investment Corporation Futures Broker Company from 1996 to 1999. Ms. Liu graduated from Beijing University with a Bachelor degree in 1996 and graduated from the Graduate School of the Chinese Academy of Social Sciences with a Master degree in 1998.

Dr. Alexander Wick, Ph.D., age 68, has been a Director of Dragon since 1998 and was the President from 2002 until his resignation effective on February 2, 2006. Dr. Wick holds a doctorate degree in synthetic organic chemistry from the Swiss Federal Institute of Technology and has completed post-doctoral studies at Harvard University. He has had leading positions in the pharmaceutical research departments of F. Hoffmann-La Roche in the United States and Switzerland and Synthelabo in France (Director of Chemical Research and Development) for over 25 years in the field of antibiotics, prostaglandins, vitamins, cardiovascular CNS and AIDS. In 1995 he created the fine chemicals company Sylachim S.A., a 100% subsidiary of Synthelabo, active in chemical intermediates and API's for the world's largest pharmaceutical companies (turnover of over 100 million Euros) and was its President until its acquisition by the German conglomerate mg Technologies (Dynamit-Nobel GmbH) in 2001.

Dr. Yiu Kwong Sun, M.D., age 62, has been a Director of Dragon since 1999. Dr. Sun graduated from the University of Hong Kong Faculty of Medicine in 1967. He is a Founding Fellow of the Hong Kong College of Family Physicians and a Fellow of the Hong Kong Academy of Medicine. Since 1995, he has served as the Chairman of the Dr. Sun Medical Centre Limited, which has been operating a network of medical centers in Hong Kong and China for the past 20 years. He is also the Administration Partner of United Medical Practice, which manages a large network of medical facilities throughout Hong Kong and Macau. Dr. Sun has been a member of the Dr. Cheng Yu Tung Fellowship Committee of Management of the University of Hong Kong Faculty of Medicine since 1997.

Mr. Peter Mak, age 45, is a fellow of the Chartered Association of

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Certified Accountants in UK as well as a fellow of the Hong Kong Institute of Certified Public Accountant. Mr. Mak was formerly the Managing Partner of Arthur Andersen Southern China and also a partner of Arthur Andersen Worldwide. Through his twenty years of accounting and financial practices, Mr. Mak has extensive knowledge and experience in Chinese and international accounting standards. He is also the independent director or financial advisor for several public companies listed in United States and Hong Kong.

Mr. Heinz Frey, age 68, graduated from University of Berne, Switzerland in 1966, has 30 years of experience in the telecommunication industry, security manufacturing and service industry. He has broad experience in the management of various sizes of companies with global presence, financing and controlling of international companies, leading development, production, sales and finance departments. He is also a board member of various companies.

59

Mr. Jin Li, age 38, is currently a senior advisor of Phycos International Co., Ltd. Prior to joining Phycos, he was a partner at the international law firm, Linklaters. Mr. Li studied biochemistry at Peking University in China and received his Master of Science degree in Biochemistry from the University of Michigan and his doctoral degree from Law School of University of Columbia. He has more than ten years of experience in international IPOs, M&A and business transactions.

Description of Executive Officers

The following sets forth our executive officers.

Name	Position	Age
Yanlin Han	Chief Executive Officer and Director	42
Zhanguo Weng	Vice President, China Operation	51
Alexander Wick	President until February 2, 2006	68
Maggie Deng	Chief Operating Officer	38
Garry Wong	Chief Financial Officer	35

For a description of Mr. Han, Mr. Weng and Dr. Wick, please see their biographies above under "Description of Current Directors."

Maggie Deng is the Chief Operating Officer of the company, holding bachelor degree from Tsinghua University in China. Ms. Deng has over 10 years of experience working in or with public companies as investment banker, mainly on IPOs and secondary offering for Chinese companies on domestic stock exchange as well as international ones. Ms. Deng was the senior manager of China International Capital Corporation, a Morgan Stanley joint venture investment banking firm in China, from 1998 to 2001. Ms. Deng moved to Canada in 2001 and held a position of Assistant to President in a start-up biotech company in Vancouver.

Garry Wong is the Chief Financial Officer of the Company since January 2005. Prior to his current position, Mr. Wong served as our Executive Assistant to President and CEO from February 2002 to January 2005. Before joining us, Mr. Wong was a team member of the Global Mergers and Acquisitions Group at Nortel Networks since 1996. He managed and executed transactions consisting of acquisitions, divestitures, equity investments, spin-offs, public market listing and joint ventures, in Europe, North America, Asia and the Middle East. Mr. Wong is a Chartered Financial Analyst who received an International MBA degree from York University, Canada with double majors in Corporate Finance and Greater China studies and a Bachelor degree in Business Administration from University of Hong Kong.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Director's Compensation

Directors are not routinely compensated for their services. However, from time to time, Board members are awarded stock options as determined by the Board. The exercise price of the options is based on the fair market value of the underlying shares of common stock at the time of grant. No directors receive any compensation during 2005. At a directors meeting held on January 12, 2005, Ms. Liu, Dr. Sun and Dr. Wick were granted options to purchase 200,000, 200,000, and 400,000 shares of common stock, respectively, at \$1.18 per share which represented the closing per share price as of that date. At a directors meeting held on September 30, 2005, Mr. Han, Mr. Weng, Ms. Liu, Dr. Wick,, Dr. Sun, Mr. Mak, Mr. Frey and Mr. Li were granted options to purchase 500,000, 300,000, 200,000, 400,000, 200,000, 200,000, 200,000 and 200,000 shares of common stock, respectively, at \$0.74 per share which represented the closing per share price as of that date.

60

Audit Committee

During 2004, we previously had an audit committee that consisted of Mr. Philip Yuen Pak Yin and Dr. Yiu Kwong Sun. During the latter part of 2004, Mr. Yuen resigned from the audit committee. In light of Mr. Yuen's resignation that left one remaining member, the audit committee functions were then handled by the Board of Directors. On September 30, 2005, the Board appointed Mr. Mak, Mr. Frey and Mr. Li to the Audit Committee. Mr. Mak, the Chairman of the Audit Committee, is an expert within the meaning of Item 401 of Regulation S-B

Code of Ethics

The Company has adopted a Code of Ethics that is applicable to the officers, directors and employees of the Company, including the Company's principal executive officer, principal financial officer, principal accounting officer, controller, or persons performing similar functions. The Code of Ethics is available on the Company's website at www.dragonpharma.com. Amendments to and waivers from the Code of Ethics will also be disclosed on the Company's website.

ITEM 10. EXECUTIVE COMPENSATION

Compensation Summary

The following table summarizes all compensation earned by or paid to our Chief Executive Officer and other Executive officers who received compensation in excess of \$100,000 during year 2005.

Summary Compensation Table

	Annual Compensation				Long Term Comp	
	Year	Salary	Bonus (\$)	Other Annual Compensation (\$)	Awards	P
Restricted Stock Award(s)					Securities Underlying Options (#)	P

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Yanlin Han C.E.O.	2005	\$156,263	-0-	-0-	-0-	500,000
Alexander Wick President	2005	\$0 (1)	-0-	-0-	-0-	800,000
	2004	\$0 (1)	-0-	-0-	-0-	-0-
	2003	\$0 (1)	-0-	-0-	-0-	200,000
Maggie Deng C.O.O	2005	\$104,175	-0-	-0-	-0-	400,000
Garry Wong C.F.O.	2005	\$106,654	-0-	-0-	-0-	400,000

- (1) Dr. Wick was appointed President of the Company in September 2002 and resigned on February 2, 2006. He is not paid for his services, but is reimbursed for expenses he incurs in the course of performing his duties for us. He received an option to purchase 200,000 shares of common stock at \$0.68 per share in 2003 and options to purchase 400,000 shares of common stock at \$1.18 per share and 400,000 shares of common stock at \$0.74 per share in 2005.

61

Option Grants in 2005

The Company granted options to purchase 2,260,000 shares at an exercise price of \$1.18 per share on January 12, 2005 and 3,660,000 shares at an exercise price of \$0.74 per share on September 30, 2005.

Aggregated Option Exercises in Last Fiscal Year and Ten-Year Options/SAR Repricings

There was no repricing of options for the fiscal year ended December 31, 2005.

Fiscal Year End Option Values

The following table sets forth for our executive officer named in the Summary Compensation Table the number and value of exercisable and un-exercisable options as at December 31, 2005.

Name	Shares Acquired on Exercise	Value Realized (\$)	Number of Securities Underlying Unsecured Options at December 31, 2005		Value at De Exerc
			Exercisable	Unexercisable	
Yanlin Han	0	--	500,000	-	0
Alexander Wick	0	--	1,000,000	-	0
Maggie Deng	0	--	400,000	-	0
Garry Wong	0	--	420,000	-	0

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

(1) Based upon the closing price of a share of our common stock of \$0.64 per share at December 31, 2005.

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The following table shows the amount of our common stock (symbol: TSX:DDD; OTCBB:DRUG; Berlin, Frankfurt and XETRA: DRP) beneficially owned (unless otherwise indicated) by each shareholder known by us to be the beneficial owner of more than 5% of our common stock, by our named executive officer and current directors and the executive officers and directors as a group. Except as otherwise indicated, all information is as of March 15, 2006

Name & Address of Beneficial Owner	Shares Beneficially Number	Owne Per
Yanlin Han Chief Executive Officer and Director c/o 1055 Hastings Street, Suite 1900 Vancouver, British Columbia V6E 2E9	31,651,403 (2)	50.

62

Name & Address of Beneficial Owner	Shares Beneficially Number	Owne Per
Zhanguo Weng Vice President, China Operation and Director c/o 1055 Hastings Street, Suite 1900 Vancouver, British Columbia V6E 2E9	9,200,401 (3)	14.
Xuemei Liu Director c/o 1055 Hastings Street, Suite 1900 Vancouver, British Columbia V6E 2E9	4,650,200 (4)	7.4
Alexander Wick, President and Director	1,300,000 (5)	2.1%
Yiu Kwong Sun, Director	1,100,000 (6)	1.7
Peter Mak, Director	200,000 (7)	0.3
Heinz Frey,		

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Director	200,000 (7)	0.3
Jin Li, Director	200,000 (7)	0.3
Maggie Deng Chief Operating Officer	400,000 (7)	0.6
Garry Wong Chief Financial Officer	420,000 (7)	0.7
All directors and executive officers as a group (10 persons)	49,322,004 (8)	78.

(1) Except as otherwise indicated, we believe that the beneficial owners of the common stock listed above, based on information furnished by such owners or publicly available, have sole investment and voting power with respect to such shares, subject to community property laws where applicable. Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock subject to options or warrants currently exercisable, or exercisable within sixty days, are deemed outstanding for purposes of computing the percentage ownership of the person holding such option or warrants, but are not deemed outstanding for purposes of computing the percentage ownership of any other person.

(2) Includes options to purchase 500,000 shares.

(3) Includes options to purchase 300,000 shares.

(4) Includes options to purchase 400,000 shares.

(5) Includes options to purchase 1,000,000 shares.

63

(6) Includes 400,000 shares of common stock subject to options exercisable within sixty days. Also includes 600,000 shares of common stock owned by Yukon Health Enterprise for which Mr. Sun serves as director and officer.

(7) Represents options exercisable within sixty days.

(8) Includes options and warrants to acquire 4,020,000 shares of common stock.

Compliance with Section 16 of The Securities Exchange Act of 1934

Section 16(a) of the Exchange Act requires our executive officers and directors to file reports of ownership and changes in ownership of our common stock with the SEC. Executive officers and directors are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. Based solely upon a review of Forms 3, 4 and 5 delivered to us as filed with the Securities and Exchange Commission, we believe that our executive officers and directors and persons who own more than 10% of our common stock timely filed all required reports pursuant to Section 16(a) of the Exchange Act.

Equity Compensation Plan Information

Our shareholders approved a share option plan at our Annual Meeting held on December 18, 2001, authorizing 4,500,000 shares for issuance under the plan. At our Annual Meeting held on August 12, 2005, our shareholders approved another share option plan authorizing the issuance of a further 15,000,000 shares. The following table provides aggregate information as of December 31, 2005 with

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

respect to all compensation plans (including individual compensation arrangements) under which equity securities are authorized for issuance.

Plan Category	A	B	Number of securities remaining as of the end of the reporting period, plus the number of securities to be issued upon exercise of outstanding options, warrants and rights under equity compensation plans (excluding securities that are not expected to vest)
Equity compensation plans approved by security holders	6,437,500	\$0.92	12,780
Equity compensation plans not approved by security holders	0	-	-
Total	6,437,500	\$0.92	12,780

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

During the past two years, we have been a party to transactions involving certain of our directors or executive officers. See also Notes 4, 7 and 21(b) to our financial statements.

64

On April 4, 2004, we entered into an agreement with Dr. Longbin Liu, a former director, and his affiliate to settle the amount owing to us from his acquisition of the Hepatitis B Vaccine Project as well as cancellation of the Patent and Project Development agreements between the parties. Under the terms of the settlement agreement, the G-CSF, Insulin and Hepatitis B Projects, including the rights of ownership and development obligations would revert to Dr. Liu.

In exchange, Dr Liu agreed to pay us the \$3,710,000 in principal and interest owing under the Hepatitis B Project as well as reimburse us \$1,330,000 that had been paid previously under the Patent and Project Development agreements. All amounts were due December 31, 2004 and the warrants granted to Dr. Liu under the Patent Development agreement were cancelled. Dr. Liu has agreed to provide 2,600,000 common shares of the Company, to be held in escrow, as security for the amounts owing.

Dr. Liu did not repay the amounts owing on December 31, 2004 and forfeited the 2,231,000 common shares of the Company that were held in escrow for as security for the amount owing. These shares, which were subsequently cancelled by the Company, were valued at \$2,606,486 and resulted in the Company realizing a recovery of \$2,106,486 of the amount that had been written-down in prior years.

Dr. Liu is still indebted to the Company in the amount of approximately \$2.48 million with this debt accruing interest at the rate of 6% per annum. This

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

debt is carried on the Company's books at \$100. The Board is considering what steps, if any, it intends to take against Dr. Liu.

Subsequent to December 31, 2005, the Company disposed of the cell line, and all applicable obligations relating, thereto, being developed for the Company to enter the European market. The cell line was sold to AS Biotech AG, a Swiss company controlled by Dr. Alexander Wick, a Director of the Company who was also the President of the Company prior to the transaction. The cell line had a carrying value of \$0 and was sold for \$1 million and the assumption of all obligations under the agreement.

ITEM 13. EXHIBITS

(a) Exhibits

Exhibit Number	Name
2.1(a)	Share Exchange Agreement with First Geneva Investments
3.1(a)	Certificate of Incorporation and Amendments <ul style="list-style-type: none">a. Certificate of Incorporationb. Certificate of Amendment, dated June 19, 1997c. Certificate of Amendment of Articles of Incorporation, dated September 21, 1998
3.2	Amended and Restated Bylaws
10.1(a)	Sino-Foreign Co-operative Company Contract
10.2(a)	Sino-Foreign Joint Venture Contract Between The Nanjing Medical Group Company Limited and Allwin Newtech Ltd.
10.3(b)	Consulting Agreement with E. Pernet Portfolio Management dated June 15, 1999
10.4(b)	Amendment to Sino-Foreign Co-operative Company Contract
10.5(c)	Contract to lease 25 acres of land in Yanjiao, China
10.6(c)	Sample Employment Agreement for technicians/employees
10.7(d)	Marketing and License Agreement Between Allwin Biotrade and Fargin S.A.
10.8(d)	Marketing and License Agreement Between Allwin Biotrade and Duopharma (Malaysia) SDN.BHD
10.9(d)	Marketing and License Agreement Between Allwin Biotrade and Yoo & Yoo Biotech Co. Ltd.
10.10(d)	Acquisition Agreement Among Dragon Pharmaceuticals Inc., Alphatech Bioengineering Limited, Longbin Liu and Philip Yuen
10.11(e)	<ul style="list-style-type: none">a. Sino Foreign Joint Venture Contract Between The Nanjing Medical Group Company Limited and Allwin Newtech Ltd.;b. Amendment dated November 24, 2000;c. Amendment dated December 16, 2000; and

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

- d. Confirmation letter of control from The Nanjing Medical Group Company Limited to Allwin Newtech dated December 16, 2000
- 10.12(f) Joint research project with the Company and Shenzhen Kelong Chuang Jian Enterprise Co.
- 10.13(f) Patent Development Agreement with Dr. Longbin Liu and Novagen
- 10.14(f) Project Development Agreement with Dr. Liu
- 10.15(g) 2001 Stock Option Plan
- 10.16(h) Waivers of Certain Conditions to the Shares Purchase Agreement
- 10.17(h) Escrow Agreement among Dragon Pharmaceutical, Oriental Wave Holding Limited, Yanlin Han, Zhanguo Weng and Xuemei Liu.
- 10.18(i) Collaboration Agreement Among Transworld Pharmaceuticals Corporation Inc. and Toray Trading Corp. and Dragon Pharmaceutical Inc.
- 10.19(i) Agent Agreement Among Allwin Biotrade, Inc., Jiangsu Wuzhong Industry Co. Ltd. and Jiangsu Wuzhong Industry Co. Ltd. Suzhuo Zhang Kai Bio-Pharmaceuticals Plant
- 10.20(i) Development and Manufacturing Agreement Between Dragon Pharmaceutical Inc. and Polymun Scientific Immunbiologische Forschung GmbH
- 10.21(i) Agreement for Advance and Long Term Supply of Products between Aurobindo (Datong) Bio-Pharma Co. Ltd. and Shanxi Weiqida Pharmaceutical Co. Ltd.
- 10.22(i) Technology Transfer Agreement between Shanxi Weiqida Pharmaceutical Co., Ltd. and Alpha Process Trust Reg.
- 66
- 10.23(i) Manufacturing Agreement for Dry-freeze Levofloxacin Injectable by and between Shanxi Weiqida Pharmaceutical Co. and Shanxi Pude Pharmaceutical Co. Ltd.
- 10.24(i) Technology Transfer Agreement between Shanxi Weiqida Pharmaceutical Co., Ltd. and Alpha Process Trust Reg.
- 10.25(k) 2005 Stock Option Plan
- 10.26 Purchase Agreement between the Company and AS Biotech AG
- 23.1 Consent of Ernst & Young LLP., Chartered Accountants
- 23.2 Consent of Webb & Company, P.A.
- 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
- 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

32 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act

99.1(j) Code of Ethics

-
- (a) Previously filed with Dragon's initial registration statement on Form 10-SB, filed with the SEC on November 4, 1999.
 - (b) Previously filed with Dragon's initial registration statement on Form SB-2, filed with the SEC on May 15, 2000.
 - (c) Previously filed with Dragon's amendment no. 1 to registration statement on Form SB-2 filed with the SEC on August 3, 2000.
 - (d) Previously filed with Dragon's amendment no. 3 to registration statement on Form SB-2 filed with the SEC on October 20, 2000.
 - (e) Previously filed with Dragon's amendment no. 5 to registration statement on Form SB-2 filed with the SEC on December 26, 2000.
 - (f) Previously filed with Dragon's Form 10-K filed with the SEC on April 1, 2002. (g) Incorporated by reference to Dragon's proxy statement for the Annual Meeting held on December 17, 2001.
 - (h) Incorporated by reference to Form 8-K filed on January 18, 2005

67

- (i) Incorporated by reference to Form 8-K filed on March 2, 2005, portions of which have been omitted for confidential treatment.
- (j) Incorporated by reference to Form 10-KSB for the year ended December 31, 2004 filed on April 23, 2004.
- (k) Incorporated by reference to the Company's proxy statement for 2005.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

For the year ended December 31, 2005 Moore Stephens, until their resignation on May 5, 2005, and Ernst & Young were engaged by us to provide non-audit services. For the year ended December 31, 2004 Webb and Company were engaged by Oriental Wave to provide non-audit services. During the years ended December 31, 2005 and 2004 the following fees were paid for services provided by Ernst & Young and Moore Stephens and by Webb and Company.

As the acquisition of Oriental Wave Holdings Ltd was deemed to be a reverse-take-over transaction, Oriental Wave is considered to be the parent company for accounting purposes. The independent accountant for Oriental Wave for the year ended December 31, 2004 was Webb & Company P.A.

For the year ended December 31, 2005, Moore Stephens and Ernst & Young were engaged by us to provide non-audit services. For the year ended December 31, 2004 Webb and Company were engaged by Oriental Wave to provide non-audit services. During the years ended December 31, 2005 and 2004, the following fees were paid for services provided by Ernst & Young and Moore Stephens and by Webb and Company.

Audit Fees. The aggregate fees paid for the annual audit of financial statements included in our Annual Report for the year ended December 31, 2005 and 2004 and the review of our quarterly reports for such years, amounted to approximately \$210,000 paid to Ernst & Young and \$174,800 paid to Webb & Company, respectively.

Audit Related Fees. For the years ended December 31, 2005 and 2004 we paid \$Nil and \$Nil to Ernst & Young and Webb and Company for other audit related

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

fees.

Tax Fees. For the year ended December 31, 2005 and 2004, we paid no fees to Ernst & Young and Webb and Company for tax fees.

All Other Fees. For the years ended December 31, 2005 and 2004, we paid no fees to Ernst & Young and Webb and Company for any non-audit services.

The above-mentioned fees are set forth as follows in tabular form:

	2005	2004
	----	----
Audit Fees	\$210,000	\$174,800
Audit Related Fees	-0-	-0-
Tax Fees	-0-	-0-
All Other Fees	-0-	-0-

68

Audit Committee Approval of Audit and Non-Audit Services of Independent Accountants

The Audit Committee approves all audit and non-audit services provided by the independent auditors. These services may include audit services, audit-related services, tax services and other services. The independent accountants and management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent accountants, and the fees for the services performed to date. No non-audit services were provided by our independent accountants in 2005.

69

SIGNATURE

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 28, 2006

Dragon Pharmaceutical Inc.,
a Florida Corporation

/s/ Yanlin Han

Yanlin Han, Chief Executive Officer
(Principal Executive Officer)

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures

Date

/s/ Yanlin Han

March 28, 2006

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 10KSB

Mr. Yanlin Han, Chairman of the Board

/s/ Zhanguo Weng

March 28, 2006

Mr. Zhanguo Weng, Director

/s/ Dr. Yiu Kwong Sun

March 28, 2006

Dr. Yiu Kwong Sun, Director

/s/ Dr. Alexander Wick

March 28, 2006

Dr. Alexander Wick, Director

/s/ Xuemei Liu

March 28, 2006

Ms. Xuemei Liu, Director

/s/ Peter Mak

March 28, 2006

Mr. Peter Mak, Director

/s/ Heinz Frey

March 28, 2006

Mr. Heinz Frey, Director

70

/s/ Jin Li

March 28, 2006

Mr. Jin Li, Director

/s/ Garry Wong

March 28, 2006

Garry Wong, Chief Financial Officer
(Principal Financial and Accounting Officer)

71